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ABSTRACT
Sevy Majers, Joan. D.N.P. College of Nursing and Health Sciences, Wright State
University, 2014. An Evaluation of the Chronic Disease Self- Management Program

The prevalence and costs of chronic disease continue to escalate with the aging of the
population and continued advancements in medical care. Self-management of chronic
disease may be an alternative approach to care that could assist in moving away from a
disease-oriented model to health-oriented one. Outcomes from chronic disease selfmanagement programs are promising but inconsistent across disease entities and
populations. Among the Veteran population, chronic disease self-management programs
have been implemented in a number of Veteran Affairs facilities. The purpose of this
project was to evaluate specific outcomes from the chronic disease self-management
program conducted in the five medical centers that comprise the Veterans Integrated
Services Network 10. Selected outcome variables included perceived self-efficacy,
utilization and cost of healthcare services.
Findings were consistent with some of the evidence noted in the literature review.
Although there was not a means of determining significance in perceived self-efficacy
measurements by participants after the intervention, as seen consistently in the evidence,
there were obvious differences in scores, indicating that for some of the participants the
intervention made an impact. No significant reductions in service volumes or costs
occurred six months after completion of the workshops. A small decrease was seen in the
numbers and costs of outpatient visits. Mean hospital days emergency department visits
iii

and costs increased, but not significantly. However, the sample sizes for both costs
calculated six months after the intervention for inpatient care and emergency department
visits drawn from the total population were small, , leading to the conclusion that any
financial impact that could be attributed to the intervention to these outcomes would be
considered premature at this time.
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Description of the Problem
Prevalence of Chronic Disease
Chronic diseases are defined as “permanent, nonreversible conditions that may be
expected to require a long period of supervision, observation, or care and interfere with a
person’s physical, psychological and social functioning” (Nodhturft et al., 2000, p. 507).
The prevalence of chronic disease continues to escalate. With improvement in the
management of infectious diseases, nutrition, sanitation, and hygiene measures, life
expectancy has steadily increased thus increasing the prevalence of chronic disease
worldwide (Huber et al., 2011; Lehnert et al., 2011). In 2005, nearly 133 million
Americans had at least one chronic disease. By 2020, that number is anticipated to
increase by 16% (Bodenheimer, Chen, & Bennett, 2009; DeVol & Bedroussian, 2007).
As seen in Figure 1, the prevalence of adults aged 46-64 with two or more chronic
illnesses increased 5% between the years 1999-2010. For adults over the age of 65, the
increase was 8.1% (Freid, Bernstein, & Bush, 2012).
The increases in chronic disease during this period of time were seen regardless of
sex or race (Freid et al., 2012). For those living in poverty, higher increases in prevalence
rates were observed among Hispanic adults, blacks, and for individuals between the ages
of 45-64 years.
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Figure 1
Prevalence of adults with chronic disease ages 40-64 and >65 years
between 1999-2010.

1

Significantly different from 1999–2000, p < 0.05
Source: CDC/NCHS, National Health Interview Survey. Retrieved from
http://www.cdc.gov/nchs/data/databriefs/db100.pdf

There are several factors that will contribute to the expected increase in the
prevalence of chronic disease in the United States. The first is the increasing proportion
of the aging population. The number of Americans reaching 65 years and older is
expected to reach more than 70 million by 2030 (Boult, C., Green, Boult, L., Pacala,
Snyder, & Leff, 2009). Advances in technology, aggressive disease treatments, and early
detection or screening efforts have resulted in medical care interventions for individuals
with chronic diseases that prolong life (Thorpe & Philyaw, 2012). The availability of
treatments, new procedures, or pharmaceuticals to manage diseases has also led to
increased utilization of the healthcare system by individuals with chronic disease, with
corresponding costs for these therapies (Anderson & Horvath, 2004; Borger et al., 2006;
Druss, Marcus, Olfson, Tanielian, Elinson, & Pincus, 2001; Lehnert et al., 2011; Thorpe
& Philyaw, 2012).
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A second factor contributing to the increase in chronic disease is the presence of
risk factors that place individuals at higher risk for the development of chronic disease,
particularly in the U.S. (Bodenheimer et al., 2009; Thorpe & Howard, 2006). Three
lifestyle behaviors, smoking, inadequate physical activity, and unhealthy dietary
practices, have been linked to chronic disease and early mortality (Ford, Bergmann,
Boeing, Li, & Capewell, 2012National Center for Chronic Disease Prevention and Health
Promotion, 2012). As a major risk factor in the development of chronic disease the
greatest concern is obesity. According to Sturm, as cited by Thorpe and Philyaw (2012),
the rising prevalence of obesity is “equivalent to 20 years of aging on the number of
chronic conditions an individual has” (p. 411). Further, obesity has been related to the
increasing prevalence of such chronic diseases as diabetes, heart disease, and
hypertension.
Data indicate that cancer; cardiac disease; pulmonary, particularly chronic
obstructive pulmonary disease; diabetes; and cerebrovascular diseases remain the most
prevalent and costliest chronic illnesses in the U.S. (Bodenheimer et al., 2009; Thorpe &
Philyaw, 2012). The current American healthcare system remains fragmented. Healthcare
is uncoordinated and results in ineffective management of complex chronic care (Boult et
al., 2009). Consequently, as the number of chronic conditions increases, individuals with
chronic diseases consume most of the available healthcare resources and utilize more
services, all at an increasingly greater cost (Boult et al., 2009; Druss et al., 2001; Lehnert
et al., 2011).
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Healthcare Costs
Data show that the United States spends the highest dollar amount in the world on
healthcare per capita (Bodenheimer et al., 2009; Boult et al., 2009; Thorpe & Howard,
2006). Much of the growth in healthcare spending is related to the care of individuals
with chronic conditions. Individuals with five or more chronic conditions, having
Medicare as their primary payer source, account for nearly two-thirds of all Medicare
spending. The cost burden increases to 80% of Medicare spending when individuals with
four or more conditions are added to this group (Boult et al., 2009). Hospital spending
has consistently been the largest component of these expenditures (see Figure 2).

Figure 2
2011 Medicare healthcare expenditures (in billions of dollars).
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Note: Original cost data was retrieved from Centers of Medicare and Medicaid,
National Health Expenditures 2011 Highlights. Retrieved from
http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trendsand-Reports/NationalHealthExpendData/downloads/highlights.pdf
As reported by the Centers for Medicare and Medicaid, the highest rates of
hospital admission in 2010 included five chronic conditions.
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These conditions are:


heart failure;



diabetes;



chronic obstructive pulmonary disease;



hypertension; and



amputations due to diabetes (Squires, 2011).

In 2006-2007, healthcare spending was calculated to be 16%-17% of the gross
domestic product (GDP). This figure remained fairly constant for the years 2009-2011.
Recently, perceived reductions in the use of medical services have been attributed to the
recent recession which resulted in significant efforts by payers to restrict coverage for
costly services, efforts by employers to curtail costly healthcare services, and reduced
participation in insurance plans (Keehan et al., 2012). Should the population that requires
services increase as baby boomers become eligible for Medicare and projections for
prevalence of chronic disease continue, the cost of healthcare will grow an average of
6.2% annually and reach nearly 20% of the GDP, or half of the federal budget, by 2021
(Keehan et al., 2012).
The Veteran Population: Chronic Disease Prevalence and Costs
Although there are a few studies specific to chronic disease among Veterans,
those that were identified indicated that the prevalence of chronic disease burden was
similar to the general population (Larson & Welch, 2007; Villa, Harada, Washington, &
Damron-Rodriquez, 2003). As with other populations in the country, studies have also
indicated that utilization of healthcare services and cost of care has increased with the
number of chronic conditions identified by Veterans (Weiss, 2007; Yu et al., 2003).
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Depending on age, income, access, and other variables, Veterans may have
options other than a Veteran’s medical center for healthcare services (VA). Veterans
enrolled in the VA system are assigned to priorities based on their service-connected
disability and income. Priorities occur in levels one through eight. Levels seven and eight
are Veterans without service-connected disabilities; these individuals are required to
provide co-payments for the services they receive. Veterans in the other priority levels
have been assessed with some type of a service-connected disability and/or are
considered to be low income (Petersen, Byrne, Daw, Hasche, Reis, & Pietz, 2010).
Previous studies of the VA system have indicated that Veterans who rely on the
VA medical systems are generally under the age of 65, live near a local medical center,
and are usually designated as one of the higher VA-determined priority categories.
Additionally, these Veterans are likely to be minorities and of lower income. These same
studies indicated that nearly 25% of Veterans over the age of 65 who are Medicare
beneficiaries receive their inpatient care at solely VA facilities. As noted by Petersen et
al. (2010), Veterans who utilized both Medicare and VA services had more diagnoses
than those who utilized VA services exclusively. This supports the supposition that the
composition of aging Veterans with chronic disease is comparable to the composition of
the aging population in general. Despite access to VA services or other providers for
Veterans over the age of 65, there is evidence of higher prevalence of diabetes, arthritis,
and cardiovascular disease among this population. According to the experts, Veterans are
more likely to report poorer health outcomes than their civilian counterparts (Hoerster,
Lehavot, Simpson, McFall, Reiber, & Nelson, 2012).
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In August of 2012, the Centers for Disease Control and Prevention (CDC)
reported that age-adjusted, elderly Veterans were less likely to be in ill-health than their
non-Veteran counterparts. Male Veterans between the ages of 45-64, however, were
significantly more likely to report having two or more of nine chronic conditions. Certain
lifestyle behaviors found in this Veteran population placed them at greater risk for
chronic disease and poorer health outcomes. These Veterans indicated that they were far
more likely than the general population to have certain risk factors associated with
chronic diseases (Hoerster et al., 2012; Larson & Welch, 2007). Examples of health
behaviors included: (a) higher frequency of obesity, (b) less physical activity, and (c)
significant use of smoking materials, especially among younger Veterans (Hoerster et al.,
2012; Larsen & Welch, 2007; Widome, Littman, Laska, & Fu, 2012).
Additionally, since 1996 groups of Veterans suffering from post-traumatic stress
disorder (PTSD) and other mental disorders, alcohol abuse, or substance abuse have
presented new challenges in managing the chronic disease burden for this population.
Veterans with mental health and/or substance abuse issues, regardless of age, have
demonstrated a greater reliance on VA health services, including inpatient care,
outpatient provider visits, and pharmaceuticals, than their non-Veteran peers (Petersen et
al., 2010).
Between the years 2000-2008 the number of individuals exclusively using
services in the VA medical centers for their healthcare needs rose by 40% (National
Center for Veterans Analysis and Statistics, 2010). Costs to the VA healthcare system
have also been projected to increase dramatically over a similar period of time (U.S.
government, Office of Policy and Planning, 2002; Yoon, Scott, Phibbs, & Wagner,
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2011). The VA healthcare system is integrated and provides inpatient services, primary
care health services, health promotion, and disease prevention in clinics and outreach
areas.
The budget for the Department of Veterans Affairs has been funded by Congress
and steadily increased by an average of 3.8% annually. From this annual budget, three
major service lines are funded including: (a) Veteran Benefits; (b) Cemeteries; and (c)
Health Services, which includes medical centers, clinics, and staff. Annually, increases in
funding have varied depending on the numbers of Veterans and the conflicts in which the
country may be engaged at any given time (Scott, 2012). Total healthcare costs provided
for the Veteran population have been projected to continue grow from the current $48
billion to $ 69 billion in 2020 despite a dramatic decrease in the total numbers of
Veterans served, but with a significant increase in minority and female representation
(U.S. government, Office of the Actuary 2012; Congressional Budget Office, 2010).
There continues to be a shift from inpatient to outpatient care within the VA system. For
2002-2012, the cost of care in both areas continued to rise. From 2002-2012, acute care
admissions increased from 565,000 to 704,000 hospitalizations and outpatient visits
nearly doubled from 47 million to 87 million (U.S. government, Office of the Actuary
2012)). Just as other providers in the national healthcare system are struggling with the
rising cost of healthcare, the Department of Veterans Affairs healthcare service has been
similarly challenged to manage the cost of healthcare within its own network of
providers.
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Definitions and Conceptual Framework
These trends of rising healthcare costs demonstrate the need for alternative
models of care to mitigate the risk factors associated with chronic disease. New
approaches are needed to manage chronic disease that will contain or reduce cost and
produce value. One promising practice may be the use of self-management programs that
are designed and implemented with evidence of positive outcomes (Kass-Bartelmes,
2002; Gordon & Calloway, 2008; Thorpe & Howard, 2006).
Unlike healthcare providers that focus on disease management, self-management
programs encourage the patient to become the expert by learning to “manage the
symptoms, treatment, physical and psychological consequences and life style changes
inherent in living with a chronic condition” (Du & Yuan, 2010, p. 159). Since health is
affected by lifestyle and habits adopted by the individual, it is possible to have some
control over the factors that affect one’s health (Bandura, 2004). Why, then, do some
individuals choose to change behavior and alter or defer negative outcomes of chronic
disease and others do not? Among the various theories that offer explanations for
behavior change that benefit health, one is based on health promotion and disease
prevention by social cognitive means (Bandura, 2004).
Social cognitive theory is based on the belief that behavior is determined by what
an individual expects from the consequences of an action or his/her ability to perform a
behavior and the perceived value of the outcomes of that behavior by the individual
(Rosenstock, Streher, & Becker, 1988). Healthy behavior change is influenced by what
the individual believes the consequences to be. An individual adopts changes in health
behaviors based on (a) understanding the risks and benefits of those behaviors; (b)
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perceived confidence (known as self-efficacy) in believing that those health behaviors
can be learned; and (c) expectations that the outcomes, or goals, of the behaviors will be
achieved. Since “cognitive processes play a predominant role in the acquisition and
retention of new behavior patterns” (Bandura, 1977, p. 192), knowledge of the need for
change is necessary for the process to be successful. However, the ability to develop selfefficacy or to achieve necessary behavior change is “central” and “rooted in the core
belief that one has the power to produce desired changes in by one’s actions” (Bandura,
2004, p.144).
For self-management of chronic disease, individuals begin by cognitively learning
about disease processes, since this plays an important role in the development and
retention of new behaviors (Bandura, 1977). Learning from others is another means of
acquiring new health behaviors. Change in behavior is learned through others and can be
accomplished through demonstration or feedback from others. As an individual
successfully practices new skills or health behaviors, there is an expected increase in the
individual’s level of self-efficacy, or “the belief in one’s capabilities to organize and
execute the courses of actions required producing given attainments” (Bandura, 1977, p.
3). Incrementally, individuals develop the confidence, or a self-perceived internal state of
competence, that they are able to do what needs to be done to achieve health outcomes
and manage chronic disease (McKenzie, Neiger, & Thackeray, 2009; Marks &
Allegrante, 2005; Pearson, Matke, Shaw, Ridgely, & Wiseman, 2007).
Self-efficacy is typically measured by asking “how confident” the individual is in
mastering the tasks and specific skill sets necessary to achieve certain states (Lorig &
Holman, 2003). Self-efficacy has been viewed as the “primary determinant for task-
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oriented behavior and performance” (Harrison, Rainer, Hochwarter, & Thompson, 1997,
p. 79). Change is achieved by different means, but is “induced most readily by experience
of mastery arising from effective performance” (Bandura, 1977, p. 191). Accordingly, the
more the behavior is experienced, the greater the changes in perceived self-efficacy.
When applied to chronic disease self-management programs, self-efficacy serves
as the conceptual framework upon which these programs are based. Self-efficacy is the
confidence in one’s ability to make behavioral changes. It determines how individuals
“feel, think, motivate themselves and behave” (Bandura, 1994, p. 71). An individual
exercising strong self-efficacy and using cognitive processes will choose to make
decisions and adopt behaviors that are different to promote health and mitigate the
consequences of chronic disease.
Through self-efficacy, individuals approach decisions differently; they see them
as opportunities rather than difficulties (Bandura, 1994). Individuals can be proactive,
make choices to adapt to changes in life and circumstances, and overcome perceived
barriers, rather than simply undergo life experiences and manage stressors (Benight &
Bandura, 2004; Weng, Dai, Huang, & Chiang, 2009). Results occur or are increased
through learning mastery of self-management tasks, observation of others, persuasion by
others, and/or assessment of one’s emotional state (McKenzie et al., 2009).
When new behaviors are adopted or poor health habits are mitigated by a
structured self-management program, changes in behavior will also lead to changes in
health outcomes. With chronic disease, outcomes may be deferred when healthier habits
are adopted. Other outcomes may be affected as well, such as the use of health services
and, subsequently, lower costs to the healthcare system, as noted in Figure 3.
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Figure 3
Conceptual framework
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Adapted from AHRQ Publication 08-0311, p. 8; Marks and Allegrante, 2005,
p. 153).
The Stanford Chronic Disease Self-Management program has produced outcomes
that indicate participants have increased their self-efficacy (confidence) in managing
chronic disease and reduced their utilization of healthcare resources through fewer
emergency department visits and fewer hospitals days (Lorig, Sobel, Ritter, Laurent, &
Hobbs, 2001b; Lorig et al., 2001a). Reductions in healthcare utilization can reduce the
cost of care and allow for use of limited resources for other critical needs.

12

Purpose and Goals of the Project
The Veterans Healthcare system is divided geographically into VISNs, or
Veterans Integrated Services Networks. VISN 10 consists of five healthcare facilities in
the state of Ohio in the cities of Cleveland, Columbus, Cincinnati, Dayton, and
Chillicothe. To support the health of Veterans, prevent further deterioration of chronic
diseases, and determine if an alternative care model could affect acute care utilization, the
VISN leadership committed to implement the Stanford Chronic Disease SelfManagement Program. In addition to purchasing licensing materials, staff members and
lay personnel were trained as facilitators for the program, named Healthy U. Although
there have been several sessions held for Veterans in VISN 10, there has not yet been an
evaluation of outcomes for the program. Further, outcome evaluations reviewed in the
literature have not focused specifically on the Veteran population.
The purpose of this project was to conduct an evaluation of the program approved
for funding by the VISN 10 leadership. The specific objectives for the program
evaluation were (a) to determine whether the program led to a reduction in subsequent
acute care costs, as measured by the number of emergency visits, hospital days, and
provider visits in the six months prior to the participants’ classes compared to those that
occurred six months after completion of the classes; and (b) to assess if the participants
felt better prepared to manage their symptoms, as determined by measurement of
perceived self-efficacy prior to the intervention and immediately upon completion of an
expected four sessions of a total of six sessions of the program.
13

Acute healthcare for individuals with chronic disease has become a focal point for
the healthcare system, as evidenced by the increasing costs of hospital care. The
prevalence of chronic disease has continued to grow with the aging of the population, and
has been influenced by the availability of new medical therapies, technologies, and
medications. Since individuals with chronic illnesses are living longer and requiring
greater care for their health, they will consume more resources over their lifetimes
(Bodenheimer et al., 2009; Thorpe & Howard, 2006).
As of 2012, the cost of the current care processes had already grown to 17.9% of
the national GDP (Keehan et al., 2012). While uncertainties continue to exist with regards
to healthcare reform, there can be little doubt that increased demand for care will include
increased utilization for individuals with chronic disease as well as increased costs.
Additional services will be needed for the elderly. VA medical centers could find
themselves positioned as an integrated system that can offer programs to mitigate the
expected higher costs of acute care by promoting self-management of chronic disease
programs for their population. Evaluation of the Chronic Disease Self-Management
Program might assist in this effort by determining the impact of current program
outcomes.
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Guiding Framework
The purpose of program evaluation relates to the type of evaluation being
conducted. In this case, the evaluation was considered to be an impact evaluation, since it
focused on “immediate observable effects of a program, leading to the intended outcomes
of a program; intermediate outcomes” (Green & Lewis, as quoted in McKenzie et al.,
2009, p. 339). This process was not summative since it was not intended to evaluate the
entire program. The process was also not intended to seek opportunities for improvement
or changes in implementation, which is characteristic of a formative evaluation process.
This impact evaluation focused on the need for intermediate program outcomes for a
population that had not previously been described (McKenzie et al., 2009).
In 1999, the CDC published a framework for program evaluation that is often
used with public health programs and public health education programs (see Appendix
A). Based on the model, there are six steps to the evaluation process that should be
completed within four specific standards. The six steps outlined for program evaluation
include the following:


engage the stakeholders;



describe the program;



focus the evaluation plan;



gather the credible evidence;



justify the conclusions; and



ensure use with lessons learned (McKenzie et al., 2009).
15

The standards are provided as guidelines to be utilized during the evaluation
process. These guidelines are (a) utility standards that are to assure the needs of the user
are met, (b) feasibility standards that indicate the evaluation is to be reasonable,(c)
propriety standards that address ethics and respect for the rights of all of those affected,
and (d) accuracy standards that are intended to assure that procedures are in place so
findings are essentially correct (McKenzie et al., 2009).
Step One: Engage the Stakeholders
Program evaluation begins with engagement of the original stakeholders, those
groups with a vital interest in the program. Stakeholders are the groups or individuals that
may (a) increase credibility to the evaluation process, (b) fund or authorize the program
and its continuation, or (c) serve to implement program activities (Center for Disease
Control and Prevention Model, 2006).
Among these individuals and groups were the Veterans who served as voluntary
participants in the program, the master trainers who implemented the initial interventions
and subsequently trained additional intervention leaders, and leadership members of the
medical centers for VISN 10 who funded the program and set the strategic direction for
Primary Care. Additional stakeholders who were identified included members of the
Institutional Review Boards and Research and Development Committees for the sites
involved in the evaluation.
The settings for the intervention, the Chronic Disease Self-Management Program,
included the five facilities already identified and a number of affiliated clinics in VISN
10 in the state of Ohio. Master trainers were responsible for the training of other
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workshop leaders and for the quality of the training they received in the Stanford Chronic
Disease Self-Management Program.
As noted in the literature, organizational and political environments and
relationships of the stakeholders involved in the program can impact the evaluation
process (Holder & Zimmerman, 2009). The Chronic Disease Self-Management Program
for VISN 10 was originally identified and brought forward to the VISN 10 leadership for
approval by the Health Promotion Manager in Dayton. An initial three-year licensing fee
was required by Stanford University. Participants may have had a co-payment for the
program. As federal funding continues to be a source of concern based on the rising
deficit and increasing costs, all programs will be reviewed for their contribution to the
Veteran population and to the VA medical system. Given this challenging environment
and the expectations of stakeholders within it, measuring outcomes from the selfmanagement program became of paramount importance.
The master trainers for Healthy U in VISN 10 held monthly conference calls. The
coordinator for the group was the Health Promotion Manager at the Dayton Veterans
Medical Center. The initial three- year funding for the program, class materials, and
leader training, was approved by the leadership of the VISN. Salaries for staff trained to
serve as leaders were paid by the departments to which each was assigned. The master
trainers and the leadership for VISN 10 were advised and supportive of the program
evaluation project.
Step Two: Description of the Program
A program evaluation model requires a description of the program to be evaluated
in the second step.
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Specifically, there are three sets of tasks related to the self-management of chronic
conditions:


learning the necessary medical regimen , including medications or
diet;



maintaining or changing behaviors needed to manage the changes
in one’s life as result of the chronic disease; and



dealing with the emotional consequences related to having a
chronic condition (Lorig & Holman, 2003).

Specific skills that participants were taught in the self-management
programs included (a) problem-solving, (b) decision-making, (c) increasing
knowledge of useful and available resources, (d) improving communication and
forming relationships with healthcare providers, and (e) taking action (Lorig &
Holman, 2003; Pearson et al., 2007).
The initial structured self-management programs were developed by
Stanford University and focused on single chronic disease entities, such as
diabetes, osteoarthritis, and asthma. Subsequently, Stanford University developed
a revised, inclusive program. This program consists of six workshops presented
weekly to participants with any chronic disease. The purpose of this program is to
build participants’ confidence in managing their health and maintaining active,
fulfilling lives and to teach participants the skills of chronic disease selfmanagement. Each participant was provided a copy of a Stanford University book
entitled, Living a Healthy Life with Chronic Conditions: Self-Management of
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Heart Disease, Arthritis, Diabetes, Asthma, Bronchitis, Emphysema & Others
(Lorig, Holman, Sobel, Laurent, Gonzalez, & Minor, 2000).
In the six week schedule, the content was covered as indicated from the
book utilized as a reference (see Appendix B). Based on the licensing agreement,
leaders were not permitted to deviate from the script designed by Stanford
University. To demonstrate competency, each leader was expected after
completing his/her training to partner with another leader or master trainer and
teach two workshops. Other sessions could monitored by a master trainer to
assure adherence (accuracy of the standardized information delivered) and
competency (ability to “engage the participants effectively”) in the program
(Frank, Coviak, Healy, Belza, & Casado, 2008, p. 6). These measures
demonstrated the ways in which the program addressed fidelity to proper
implementation of the intervention. When fidelity, defined as “adherence or
faithfulness to the procedures that compose an intervention” is compromised,
testing an intervention and its measured outcomes can be compromised, a reason
for incorporating such indicators into program evaluation measures (Frank et al.,
2008, p. 5).
Each week, participants learned new skills to manage their symptoms. In
particular, in each session participants were expected to practice and apply the
steps for problem-solving and action planning. These processes were critical for
participants to develop or improve their self-efficacy.
Participants were free to identify a problem that they wished to work on
each week. This may have been the most difficult part of the program for some
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(Lorig et al., 2000). Participants were asked to select at least one problem, list
their ideas to resolve the problem, and choose at least one strategy to try for the
coming week. Once selections were made, participants then developed their
specific action plans for that week. As noted in the literature, successful action
planning is a vital process in the development of self-efficacy since the practice of
setting and achieving goals fosters self-confidence.
Action plan steps included (a) what they would do in the coming week to
assist with self-management, (b) the amount of time they would devote to the
activity they would do, (c) the specific time the activity would be done or where it
would be done, and (d) the frequency with which the activity would be done.
Participants were then expected to assign their own level of confidence to this
action plan based on a scale of one to 10. No scores below a rating of seven were
accepted.
Assessing the results of participants’ action plans occurred in subsequent
classes. Participants reported on their action plans, including any barriers they
encountered, and how they handled these challenges. If the initial approach to the
problem was not successful, participants were encouraged to select another
approach to the problem or utilize other resources in solving their problem.
Participants continued to work on their problem of choice throughout the
program. When a participant discovered that particular problems could not be
resolved at the time of the program, program leaders suggested that participants
select a problem that would be more appropriate to work on while they were in
the program (Lorig et al., 2000).
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Although the sessions were scripted, they were also interactive. Group
members were supportive of one another during the sessions. Exercises included
discussions between participants and sharing of results. Additionally, participants
identified individuals with whom they could communicate during the week to
support them in their self-management efforts and action plans.
Step Three: Focus the Evaluation Plan
The evaluation plan was developed with the assistance of the Health
Promotion Program Manager at the Dayton Medical Center and presented to the
master trainers at the other VA medical centers for input and support. The
demographic variables that were included in the evaluation included (a) age, (b)
sex, and (c) race.
The outcome objectives for program evaluation were agreed upon by the
master trainers to assess the impact of the program. The first outcome, utilization
of healthcare services and measured pre- and post-program, was chosen because
the program stakeholders were interested in determining whether or not this
alternative model of care for the Veteran population would result in cost
reductions, thereby preserving resources for the provision of other programs and
services. The second objective, measuring participants’ perceived confidence to
manage their chronic disease, their perceived self-efficacy, was documented in the
literature to be commonly related to successful self-management programs.
Perceived self-efficacy was to be measured by a survey developed by Stanford
University and administered to participants who had completed four of six
program sessions.
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Step Four: Gather Credible Evidence and Support
The program evaluation model at this point indicated the need for review
of the evidence that supported the program. The literature review included
programs that were facilitated by staff and/or lay individuals, all of whom were
managing their own chronic diseases. The only program that was reviewed in the
literature and was specific to the Veteran population was by Nodhturft et al.
(2000). This study did not, however, include measured outcomes in its results.
The VISN 10 Healthy U master trainers selected a strategy to engage
Veterans and their caregivers in self-management of chronic disease. Engagement
behaviors are defined as “actions that individuals must take to obtain the greatest
benefit from their healthcare services available to them” (Holmes-Rovner, French,
Sofaer, Schaller, Prager, & Kanouse, 2010, p. 2). Specific behaviors identified as
evidence for engagement include health promotion, health prevention, and
opportunities to seek health knowledge, all of which are directed to selfmanagement of chronic disease (Holmes-Rovner et al., 2010).
The specific program selected by the Healthy U master trainers in VISN
10 was the Stanford University Chronic Disease Self-Management Program. The
program was selected based on data obtained from the Area Agency on Aging,
Ohio Department of Aging, National Council on Aging, and Agency on
Healthcare Research and Quality reports.
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Literature Review
A search was initiated to review the evidence; it did not, however, include
disease management or patient education programs. As stated by Peterson et al.
(2007), “While patient education is necessary, it alone is insufficient” (p. 2).
Single disease self-management programs were also eliminated since the program
being implemented targeted individuals with any chronic disease or any number
of chronic diseases. Dates of studies were irrelevant, but studies were limited to
those conducted in the United States, Canada, or Great Britain, since these
populations more closely resembled the American Veteran population.
The search was initiated with the following key words: self-management
programs, chronic disease self-management programs, self-care, Veterans,
outcomes, healthcare services utilization, and self-efficacy. Boolean terms were
also utilized. Databases queried included the Cochrane Databases (all), CINAHL,
SocINDEX, and PubMed. There were very few hits and many of the same articles
were repeated across searches. Extensive searches by hand became necessary
based on reference lists of the studies obtained from searches and reports from the
Agency of Healthcare Research and Quality.
There were several well-designed studies available regarding the clinical
outcomes for single disease self-management programs. For programs in which
individuals were taught self-management skills for single diseases, a number of
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results reported improvement in clinical outcomes and reductions in costs. Other
studies reported less favorable outcomes, as noted in this literature review.
In one narrative review, there were 23 of 27 studies that measured asthma
self-management. Clinical outcomes for these studies demonstrated improved
asthma symptoms. Studies utilizing action planning tended to have improvements
more often than those that did not use action plans (Bodenheimer et al., 2009).
Eighteen additional studies were identified and separated into two groups: those
offering self-management and those only providing education for osteoarthritis.
Of the 18 studies, 12 reported improved clinical outcomes compared to their
control groups. All 10 of the self-management groups indicated improvement in
clinical outcomes; only two of the patient education groups reported
improvement, suggesting a difference between outcomes from self-management
programs and those from traditional patient education (Bodenheimer et al., 2009).
In the same narrative review noted above, 15 studies measuring asthma
self-management were analyzed to determine the effect on healthcare services
utilization and cost. Eight of the 15 studies reported reductions in hospital or
emergency department utilization. Ten studies contained data regarding
healthcare utilization, of which three reported reductions in physician visits. The
remaining seven studies did not report healthcare services utilization. Limitations
noted in the review included the difficulty in making generalized statements about
the impact of single disease self-management programs since interventions were
not standardized (Bodenheimer et al., 2009).
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An investigation funded by the Centers of Medicare and Medicaid resulted
in a meta-analysis of 53 studies of chronic disease self-management programs.
The conceptual model required that interventions assisted patients in selfmonitoring of symptoms and management of their diseases. Randomized trials
that compared outcomes from self-management intervention to controls for
patients with diabetes, osteoarthritis, or hypertension were included. Outcomes
evaluated included: (a) hemoglobin A1c, (b) fasting blood sugar, (c) pain, (d)
blood pressure, and (e) physical functioning. Thirteen studies addressed selfmanagement of hypertension, 14 studies addressed osteoarthritis, and 26 studies
addressed diabetes (Chodosh et al., 2005).
Pooled results from this meta-analysis indicated statistically and clinically
significant improvements for participants with diabetes for these single disease
self-management programs in reduction of hemoglobin A1c. Reductions in blood
pressure were also noted. Although there were statistically significant reductions
in pain for participants in osteoarthritis programs, they were determined to be not
clinically significant (Chodosh et al., 2005). The authors of this meta-analysis
noted that the quality of the studies varied, with some evidence of publication
bias. The analysis identified the need for standardizing self-management
programs, the essential elements to be defined, and the outcomes to be measured.
Similar results were noted in a structured review of disease-specific selfmanagement programs. Articles containing self-management interventions with
concurrent controls and evaluation of outcomes were reviewed. Both randomized
and non-randomized studies were included. Seventy-one trials, including five
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disease-specific groups, comprised this review, including: (a) arthritis, (b) asthma,
(c) diabetes, (d) hypertension, and (e) miscellaneous or generic self-management
programs.
A great deal of heterogeneity in the studies was identified. A moderate
effect size was detected in reduction of A1c levels for diabetics. Additionally,
some improvement in blood pressure was noted as well as fewer asthma attacks.
Evidence of publication bias was also noted in this group of studies (Warsi et al.,
2004).
A pre- and post-test study for a single disease self-management program
reported no clinically significant differences between responders and nonresponders but small to moderate increases in self-efficacy and symptom
management (ES= 0.43). However, no changes were found from baseline in
healthcare services utilization for nights hospitalized, provider visits, or
emergency department visits (Wright, Barlow, Turner, & Bancroft, 2003).
Evidence specific to the heterogeneous, or generic, Stanford Chronic
Disease Self-Management Program was limited. The literature most frequently
cited was Dr. Lorig and colleagues from Stanford University. In a study funded
by the Agency for Heath and Research Quality, randomized trials were conducted
with 952 program participants who were over the age of 40 and living in
community-based sites. Participants were assessed after six months for
improvement in outcomes. Three specific categories for outcomes were assessed,
including: (a) health behaviors, (b) health status, and (c) health services
utilization.
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The tools that were utilized to measure outcomes included the self-rated
health scale in the National Health Interview survey, a modified version of the
Health Assessment Questionnaire (HAQ) disability scale, a section of the SF-36
and SF-20 tools, and an adaptation of the Medical Outcomes Study that measures
pain (Lorig et al., 1999). Participants also reported emergency department visits,
provider visits, and hospitalizations.
After six months, program participants demonstrated significant
improvements in self-reported health behaviors, including: increased exercise,
greater frequency of cognitive symptom management, and improved
communication with physicians. Measures of health status and fatigue were also
improved. Participants who completed the program also reported fewer nights in
the hospital as compared to the control group, which was comprised of
individuals who were on a waiting list for the program (Lorig et al., 1999).
Following this study, Lorig conducted a before- and after-cohort study
with participants from Kaiser Permanente hospitals. The objective of this study
was to evaluate the outcomes of the Chronic Disease Self-Management Program
in a “real world setting” (Lorig et al., 2001, p. 256). Six hundred and thirteen
patients were recruited and 489 completed the study for baseline data and followup in one year. The same outcome measures were assessed utilizing the same
tools as the earlier investigation. This study included measurement of the
participants’ assessment of their perceived self-efficacy. As previously noted,
self-efficacy is the concept upon which the Chronic Disease Self-Management
Program is based. It is the personal confidence that must be developed by the
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participant to become a knowledgeable individual who can learn responsibility to
set goals for the tasks required to perform the behaviors and develop the attitudes
necessary for management of his or her chronic disease and experience improved
health status (Lorig et al., 1999; Marks, Allegrante, & Lorig, 2005).
Outcomes for measures of health status, health behaviors, and health
services were reported by the participants. Discussion about the psychometric
testing for the tools utilized in the study was also noted in the study. Self-reports
of health utilization were highly correlated to visits recorded in the computerized
medical records.
Outcomes measured at one year for participants completing the program
showed statistically significant improvements in self-reported health status, selfefficacy, self-reported health behaviors, and mixed results for healthcare
utilization. Statistically fewer emergency department visits were observed and
fewer (but not at a significant level) health provider visits or hospitals days were
documented (Lorig et al., 2001).
Lorig returned to the original 1999 study, Chronic Disease SelfManagement Program database, to conduct a longitudinal follow-up investigating
the retention of program effects (Lorig et al., 2001). In the original six month
study program, there had been 1,140 participants between the wait-listed controls
and those who were randomly assigned to the intervention. After the study, waitlisted individuals were offered the opportunity to participate, increasing the
sample size. Data were collected for all individuals who completed a
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questionnaire upon program entry, at one year, and at two years, resulting in a
final sample size of 831.
Three categories of self-reported outcomes were measured by mailed
questionnaire: health status, health services utilization, and perceived selfefficacy. Identical tools were utilized from the previous studies with one
exception. A social/role activity limitation scale was developed and tested for this
study.
No significant differences in baseline characteristics were identified
among the participants from the original study. Results in self-reported health
status indicated that participants rated some improvement in health status from
their original baseline prior to the program despite evidence of increased
disability over that same period of time. There was evidence of reduced use of
healthcare services but not at a significant level. Reported levels of self-efficacy,
however, were statistically significant (Lorig et al., 2001). Additionally, it showed
a modest decrease in the use of healthcare services. This study is important
because it demonstrates retention to some extent of the intervention despite
evidence of continued disability, which is expected with chronic disease.
A randomized controlled study in which the Chronic Disease SelfManagement Program was delivered for an Hispanic population produced
statistically improved self-reported health behaviors, health status (with the
exception of the use of tobacco), and self-efficacy. The purpose of the study was
to evaluate the program and its outcomes as a means of addressing the increasing
prevalence of chronic disease among Latinos. Prior to the implementation of the
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program, focus groups were held with Spanish-speaking individuals with chronic
disease to develop the course in Spanish. The protocol remained standardized,
even though it was taught in Spanish. Additionally, there were some culturally
appropriate adaptations made to the program.
The sample size was 551 Spanish-speaking participants, of whom 327
were program participants and 224 who were in the wait-list control group.
Outcome measures included health behaviors, health status, healthcare services
utilization, and self-efficacy. Tools were translated into Spanish and tested for
validity, and all measures were self-reported.
There were few baseline differences between the participant and control
groups. Initial results were measured at four months and indicated statistically
significant improvements in health behaviors, health status, and self-efficacy and
a trend in reductions in physician visits, however, no difference in hospital days
was observed. Although the results of this study were retrieved in a short period
of time after the conclusion of the program, results were re-assessed after one year
for retention of benefits. By then, the control group had been fully integrated into
the study. Healthcare behaviors and perceived health status indicated that
participants continued to make statistically significant improvements from
baseline. There were significantly fewer emergency visits in the last four months
of the year as compared to the four months before baseline (Lorig, Ritter, &
Gonzalez, 2003). The importance of this study is its cultural adaptation and use of
focus groups prior to implementation as a method to identify the key messages to
be integrated into the curriculum for the population.
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Additional studies have addressed self-management programs and
included measures of differences in self-efficacy and healthcare utilization.
Significant differences were found in measures of participants’ self-efficacy
(Farrell, Wicks, & Martin, 2004; Foster, Taylor, Eldridge, Ramsay, & Griffiths,
2009; Griffiths, Foster, Ramsay, Eldridge, & Taylor, 2007; Newbould, Taylor, &
Bury, 2006). Most of these studies did not report significant reductions in
healthcare utilization, but some indicated trends toward decreased utilization.
Results varied by study for self-reported health behaviors and self-reported health
status of individuals. For studies included in meta-analyses, comments regarding
high levels of heterogeneity among the studies were noted. Additionally, some
evidence of publication bias was identified.
A review of self-management programs led by lay leaders resulted in a
review of 17 randomized controlled trials with 7,442 participants. Seven of the 17
trials were specific to the Chronic Disease Self-Management program. Metaanalyses were performed based on outcomes for 16 of the 17 studies. No
statistical improvements were seen in hospital days. In 10 studies, a small but
significant increase was seen in perceived self-efficacy. Notations were made that
only Lorig’s studies reported reduction in emergency department visits and
provider visits. This review is significant because it demonstrates a depth of
analysis conducted on the studies with similar interventions. Significant
heterogeneity and variation in the quality of the studies was noted in the studies
reviewed and some evidence of publication bias was reported (Foster et al., 2009).
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A pilot study was conducted in a poor, rural area using a quasiexperimental pre- and post-test design. In this study, a sample of 48 adults
participated in the Chronic Disease Self-Management program. The majority of
participants were White while 10 were African American. The purpose of the
study was to evaluate program outcomes for this specific population. Self-efficacy
was measured in terms of managing health, symptoms, disease, and selfmanagement behaviors (Farrell et al., 2004). In this study, the Self-Efficacy
Health Cantril Ladder was utilized to measure self-efficacy. The sub scales for
this tool measured self-efficacy and self-management behaviors. Cognitive
symptom management was measured with a Likert-like scale, and results were
self-reported.
Outcome results indicated improvement in performing self-management
of symptoms and significant improvement in self-efficacy in managing health.
There were significant differences in ages and the number of classes attended by
group members. Limitations to the study included short-term follow-up, use of a
convenience sample, and small sample size. Strengths included application of the
CDSMP to an underserved population and the use of tools based on the selfefficacy concept to measure its effect (Farrell et al., 2004).
Lorig’s work with the Chronic Disease Self-Management program was
adapted by the National Health Service of Great Britain and labeled the Expert
Patients’ Programme. The National Health Services identified self-care as a
priority in its patient-centered approach to care. The Expert Patients’ Programme
was implemented as a policy by the National Health Services in 2001. Since its
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implementation there has been debate about the diversion of resources to it and
whether its results can effectively offset some of the costs of the healthcare
services provided by the national program (Griffiths et al., 2007; Newbould et al.,
2006). Two studies using the same database and drawn from the Final Report of
the National Evaluation of the Pilot Phase of the Expert Patients Program
examined the outcomes from the program with a sample size of 659 participants
in community settings in England (Kennedy et al., 2007; Richardson et al., 2007).
The purpose of Kennedy’s report from the nationally conducted
randomized controlled study was to communicate the results of the effectiveness
of the Expert Patients’ Programme compared to the waiting list control group.
The sample size from the national report was 629 patients with a variety of
chronic conditions who participated in the program based on the generic Stanford
Chronic Disease Self-Management. Three specific outcomes were measured:
perceived self-efficacy, self-reported healthcare status, and self-reported
healthcare services utilization. Data were collected at baseline, six months after
completion of the program, and 12 months after the program. The study, however,
only reported results from the six month period of measurement. The intervention
and control groups completed the collection at rates of 79.2% and 86.4%
respectively. There were no significant baseline differences noted between the
groups.
Consistent with previous studies, participants demonstrated significant
improvement in self-efficacy measures. Specifically, participants noted fewer
social role limitations, improved psychological well-being, lower health distress,
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more exercise, and better communication with their providers. At the same time,
however, results indicated no differences in overall healthcare services utilization.
The authors suggested that the lack of effect on utilization might have been due to
the short time allocated for follow-up. There was a small effect indicating reduced
inpatient utilization, although it was not statistically significant. Regardless, the
authors concluded that even a small reduction might have offset the cost of the
program itself. The study provided additional evidence that the CDSMP program
increased perceived self-efficacy and added a healthcare alternative for patients
with chronic disease. There was a small effect on hospital days that could have
led to reduction in the cost of acute care (Kennedy et al., 2007).
A recent meta-analysis of the chronic disease self-management program
included 18 studies of randomized controlled studies or longitudinal designs that
measured health behaviors, psychological health (including measurement of selfefficacy), physical health, and healthcare utilization outcomes. Significant
differences were found for symptom management, physical exercise, and
psychological outcomes. Consistent and sustained improvements in self-efficacy
were recorded and directly associated with self-reported changes in physical
function. Small reductions were seen in self-reported healthcare utilization at four
to six months after the intervention, but not sustained over 12 months (Brady et
al., 2013).
Evidence for the program and its effects on the population of interest,
Veterans, was limited to one article, a descriptive pilot study conducted with a
small sample in VISN 8 (Florida). The purpose of the pilot program was to
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evaluate whether or not implementation of the CDSMP was possible with a
Veteran population. The Veteran population was different from the one described
in Lorig’s studies in that individuals were predominately male, older, and had a
military background. The pilot program was conducted in six hospitals in the
network and utilized the Stanford Chronic Disease Self-Management Program.
Outcomes were retrieved from VA electronic medical records and responses to
self-administered questionnaires. A few centers elected to utilize Lorig’s outcome
tools that had previously been tested for validity and reliability. Focus groups
were conducted to collect additional information from participants about their
personal experiences in the program. Themes derived from the focus groups
included:


Veterans developed empathy with others who had a variety of
chronic diseases;



There were no perceived differences in health behavior changes,
regardless of service connection status;



Discussions focused on highlights of the individual program
experiences;



Participants reached consensus that they would recommend the
program to others; and



Leaders were encouraged to make the program known to as many
Veterans as possible.

Limitations to the study included a small sample size (N=43). There were
inconsistencies among the centers in how they evaluated the program. Some
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centers utilized Lorig’s tools while others only utilized focus groups and feedback
from the Veterans. No outcome statistics were reported, but qualitative results
indicated enhanced self-efficacy and satisfaction with the quality of life. It was
noted that there were slight decreases in use of outpatient provider visits and
emergency room visits (Nodhturft et al., 2000). The value of this study is that it
describes implementation of the program with the population of interest,
Veterans, and within a VISN.
In 2002, the Agency for Healthcare Quality and Research published a
summary of Lorig’s research which indicated that the reduction in hospital days
could have saved approximately $390.00 to $520.00 per participant due to the use
of fewer healthcare resources (Research in Action, 2002). Findings noted on the
Stanford University website stated that the program can result in the reduction of
healthcare expenditures. Further, the statement was made “with a reasonably high
degree of confidence” (Gordon & Galloway, 2008, “Summary of utilization
effects,” para. 2).
In 2013, a national study of the Chronic Disease Self-Management
programs was sponsored by the National Council on Aging. Results were shared
during a webinar. Twenty-two sites were selected across the nation to participate
in the study that was designed to assess participants’ outcomes at six and 12
months. At baseline, the sample size was 1,170 participants; at 12 months, the
sample size was 825. Outcome measures included symptom management, health
status, health behaviors, and healthcare services utilization, specifically
hospitalization and emergency department visits. Of the participants, 79%
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completed four of the six classes, as expected. Among the outcomes noted, there
was a statistically significant difference in self-reported symptom improvement
after 12 months. Emergency department visits were also noted to be significantly
reduced, with an estimated savings of approximately $740.00 per participant
(Whitelaw, Lorig, Smith, & Ory, 2013). Hospitalization rates remained
unchanged at both six and 12 months.
Evaluation of the evidence in the synthesis table (see Table 1) is based on
the United States Preventative Services Task Force Grade for Strength of Overall
Evidence, defined in Appendix C.
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INTERVENTION
OR OUTCOMES

Foster.
et al.
(2009)
Cat- I

Kennedy
et al.
(2007)
Cat- I

Farrell et
al.
(2004)
et al
Cat II-1

Lorig et
al.
(1999)
Cat-I

Lorig
et al.
(2001)
Cat-II-2

Lorig
et al.
(200
3)
Cat-I

Nodhturft
et al.
(2000)
Cat- III

Brady
et al.
(2013)
Cat-I

Whitelaw
et al.
(2013)
Cat-II-2

Chronic
disease selfmanagement
program

X
7/17
studies

X
( EPP)

X

X

X

X

X

X

X

Self-efficacy
framework

X

X

X

X

X

X

X

X

X

*

*

*

*

Self-efficacy
outcome

Healthcare
provider visits

*
*

*

NA

*
NA

*
*
*
(

NA

NA

NA

*
NA

NA

Nights or days
in hospital

Emergency
Department/
Urgent Care
visits



NA

*

NA

*

Note:* indicates statistically significant results
38

*

*

The literature that is specific to the generic self-management program designed to
assist participants is limited. The quality of evidence may be compromised by the lack of
statistical controls or possible publication bias, and two studies had small sample sizes
(Farrell et al., 2004; Nodhturft et al., 2000). However, there is evidence to indicate, in
many cases, that the Chronic Disease Self-Management Program has provided
opportunities for individuals with chronic diseases to develop the ability to increase their
confidence and skills to manage their health problems and improve their quality of life
(Brady et al., 2013).
Despite the issues identified in this review of the literature, there is compelling
evidence from some study results that the Chronic Disease Self-Management Program
has had a positive effect for participants related to their self-efficacy. Study participants
have reported positive effects on selected self-care behaviors and their health status.
Patient education has come to be seen as important, but not a “sufficient contributor to
behavior change” (Pearson et al., 2007, p. 2). In order for individuals to increase their
skills to manage their chronic disease, they must develop the confidence in their ability to
do so. This confidence is measured by the individual’s perceived self-efficacy. As
previously noted, self-efficacy is an individual’s belief in his or her ability to perform
those tasks necessary for self-management, but more importantly, the belief that the use
of the skills will produce “positive, desired outcomes” (Nodhturft et al., 2000, p. 510).
The articles synthesized in Table 1 provide evidence of increased self-efficacy
and some evidence of decreased cost. Additionally, there appears to be evidence that the
program has reduced healthcare utilization; however, findings are inconsistent and
limited to the studies conducted primarily by the founder of the program. Even if the
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reductions are not statistically significant, any reductions in cost should be considered.
The rising cost of healthcare, even for the VA, remains a challenge. Alternative
approaches to helping individuals manage their own health may reduce their use of costly
services. If applied to a large number of participants, any potential reductions could
amount to significant savings.
Summary
VISN 10 implemented the Healthy U program and has conducted several sessions
in each of the medical facilities and several of the outlying clinic centers. The Healthy U
master trainers agreed upon selection of a program evaluation framework for this process
from CDC (see Appendix I). This framework was selected because of its focus on
population health and health promotion.
The purposes for program evaluation are several, including: (a) determination of
the achievement of program objectives, (b) accountability to the decision-makers and
funders for the program, (c) improvement of the program, and (d) contribution to the
evidence base for community-based interventions (McKenzie et al., 2009).
There were six steps included in the program evaluation model and standards for
its proper implementation. The initial four steps of the program evaluation model have
been described. Step five, Justify Conclusion and Recommendations, and step six, Ensure
Use and Share Lessons Learned, occurred after project implementation. Step five of the
CDC program evaluation model occurred after program outcomes were retrieved,
measured, and analyzed. When the evaluation of the selected outcomes was completed,
the results were assessed utilizing the standards included in the program evaluation model
for utility, feasibility, propriety, and accuracy.
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Implementation and Evaluation
Population and Setting
Healthy U, the title given to the Chronic Disease Self-Management
Program designed by Stanford University, was offered at the five VA medical
facilities in VISN 10 and some of its outpatient clinics. VA Healthcare System of
Ohio (VISN 10) is one of 21 Veterans Integrated Service Networks (VISN) of the
Department of Veterans Affairs. In addition to the five VA medical facilities,
VISN 10 includes 30 community-based outpatient clinics which provide
comprehensive inpatient and outpatient healthcare to Veterans in Ohio, Indiana,
Kentucky, and West Virginia.
From January1, 2012, through the end of December, 2013, 296,478
Veterans received healthcare services at one of the medical facilities in VISN 10.
Those services may have included inpatient or outpatient care. The range of ages
for those served was from 20 to over 100 years. Of this total population, only 8%
were female. The population of VISN 10 is predominately male and Caucasian
(72.2%). Black or African-Americans are the largest group, or 11.9% of the
population. American Indian, Asian, and Native Hawaiian (or other Pacific
Islander) racial groups comprised the small remaining entities, 0.3%, 0.1%, and
0.5% respectively. The remaining variance in the total for identification of race
indicated that (a) race is not listed on the Veteran’s records (11.7%); (b) race is
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stated as unknown to the Veteran (1.1%), or (c) the Veteran declined to answer
(2.2%).
Participants who elected to join the chronic disease self-management workshop
may have included Veterans of any age. In this project, the average age was 62.3
years, the age range was 28-89 years, and the sample population was
predominately male. Participants may have had any chronic disease or any
number of chronic diseases. For the purpose of this current study, only Veterans
were included as participants since this population has been the subject of limited
study. The review of literature identified only two studies that specifically focused
on Veterans (Nelson, Wong, & Lai, 2011; Nodhturft et al., 2000). In the first
study (Nelson et al., 2011), the principles of self-efficacy were applied to
Parkinson’s disease only, and in the second study cited (Nodhturft et al., 2000),
there were no measured outcomes documented. The outcomes that were chosen
for this study included perceived self-efficacy and healthcare services utilization,
which are consistent with those identified in the literature review (Brady et al.,
2013; Kennedy et al., 2007; Lorig et al., 1999; Lorig et al., 2001; Lorig et al.,
2003; Whitelaw et al., 2013).
Barriers and Facilitators
One of the most critical components to successful implementation of the
project was identifying and establishing effective communication with the master
trainers at each of the sites. With the assistance of the Health Promotion Program
Manager at the Dayton VA Medical Center, contact was established with each of
these individuals to begin discussions regarding the next steps for implementation
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of the program evaluation. Monthly telephone conferences were facilitated by the
Health Promotion Program Manager during which status updates of the project
were discussed. This communication and their active engagement in the process
facilitated the program evaluation process. Once the master trainers agreed to
participate in the project, the next steps for implementation required identification
of procedures for approval at each of the medical centers. Despite the study
design as a program evaluation, a process for approval to conduct the project was
still required. A research proposal describing the program evaluation process was
prepared with the expectation that it would be submitted to an Institutional
Review Board for expedited review. Although this procedure may be complex for
any healthcare organization, this study involved five medical facilities affiliated
with the federal government. The Veterans Health Administration outlined (VHA)
its requirements in a handbook through a series of policies addressing research
processes and the use of data and data repositories made available for research
purposes (U.S. Government, VHA Handbook, 2009). Any one of the Veterans’
medical centers, as an individual healthcare system, is complex in itself. Being
part of a larger system such as VISN 10 or the VHA adds a further level of
complexity (Porter-O’Grady & Mallach, 2011). VISN 10 is one such complex
entity. Further, VISN 10 is part of an even more multifaceted system, the
Department of Veterans’ Affairs, a cabinet post in the federal government.
As any healthcare system evolves, it becomes increasingly more complex,
with highly networked entities and ordered processes (Clancy, 2007; Clancy,
Effken, & Pesut, 2008). The medical centers within the VISN are entities with
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unique structures and processes. The approval procedures for the project required
extensive communication with additional stakeholders within these systems, and
at different points in time, each affecting the implementation process. The
structure for Institutional Review Board Approval was governed by rules and
regulations outlined by the Department of Veterans Affairs, but were interpreted
differently, implemented differently, and consequently involved a variety of
additional stakeholders in the decision-making processes (see Appendix D).
Institutional Review Boards: Human Subject Protection
VISN 10 did not have a single Institutional Review Board for research
requests. Three Institutional Review Boards were involved, only one of which
managed requests for more than one facility. The Wright State University
Institutional Review Board served in this capacity for the Dayton Veterans
Medical Center. The Louis B. Stokes Veterans Medical Center had its own Board.
The University of Cincinnati served in this capacity for the Cincinnati Veterans
Medical Center, Chillicothe Veterans Medical Center, and the Chalmers P. Wylie
Veterans Medical Center. The VHA had previously established procedures to
govern operational activities that may be determined to constitute research (U.S
Government, VHA Handbook, 2011). In this handbook, research was defined as a
“systematic investigation (including research development, testing and
evaluation) designed to develop or contribute to generalizable knowledge” (U.S.
Government, VHA Handbook, 2011, 1058.05, p. 2). Additionally, the handbook
outlined policies related to research affecting human subjects noted in other
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federal policies, specifically Title 38 Code of Federal Regulations part 16 (38CFR16).
Expedited review and HIPAA waiver was sought from each of the
Institutional Review Boards. The required documents were drafted and forwarded
to the Wright State University IRB and included the following: study protocol
(see Appendix E), request to conduct research, request for a HIPAA waiver,
handout for the participants inviting them to join the study, research security
checklists, conflict of interest forms, resumes , and survey instruments to be
utilized. Concomitantly, discussion was initiated regarding the documentation
required by the Louis B. Stokes Institutional Review Board for the medical center
and the University of Cincinnati Institutional Review Board that governed
research activities for the Columbus, Cincinnati, and Chillicothe sites.
The project was approved, with revisions, by the Wright State University
Institutional Review Board (see Appendices H, I, J, K, L) but was not reviewed
by either the University of Cincinnati or the Louis B. Stokes VA Medical Center
Institutional Review Boards, both of which determined that the project did not
meet their criteria to be considered research (see Appendices F, G). The VHA
defines non-research activities as activities that are “not designed to produce
information that expands the knowledge based of a scientific discipline or other
scholarly field” (U.S. Government, VHA Handbook, 2011, 1058.05, p. 3). It was
the determination of these two entities that the study was to be utilized only for
internal VA purposes, such as quality improvement activities, and therefore, did
not constitute research.
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The process for obtaining data for research purposes also changed for all
VA sites shortly after these determinations were made. Although only one of the
centers had reviewed the project as research, data were to be collected from all
VISN 10 facilities, necessitating use of the new process for all data collection.
Completion of the request required review of all materials, including all IRB
decisions by additional entities within the larger VA system. At the final review
step, significant issues arose, including the inconsistencies among the IRB
processes in VISN 10. Among the many requirements, the program proposal was
to be reevaluated by the Cincinnati and Cleveland IRBs as research. Without
completion of these requirements, access to data was not going to be authorized.
As a result of these decisions, in addition to changes in the internal VA
processes, project implementation appeared to be compromised. Instead, the
request for approval of the project proposal from the Wright State University
Institutional Review Board was withdrawn; a closure report was submitted and
accepted (see Appendix M). With the study closure, project efforts were directed
to program evaluation process, which then provided access to data in an
alternative manner.
Project Implementation and Outcome Measures
Prior to the previous developments, all of the sites had been prepared to
implement the project in spring 2013. Before implementation could begin at any
of the facilities, conference calls were held with the master trainers to design the
specific procedures for communicating the status, purpose, and objectives of the
project. Discussions had been held with the trainers regarding the distribution of
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the project survey questionnaires that were to measure perceived self-efficacy (see
Appendix N). Additional sessions had been conducted with master trainers who
were unable to participate in the original discussion and for other groups of
leaders that planned to conduct the classes.
The survey that measured perceived self-efficacy utilized the six-item
Chronic Disease Self-Efficacy Scale (see Appendix O) developed and tested by
Stanford University for internal consistency and reliability with results at .91
(Lorig, Ritter, Laurent, & Hobbs, 2001).
Table 2
Characteristics of Self-Efficacy 6-Item Scale
No. of
items

Observed
Range

Mean

Standard
Deviation

Internal Consistency
Reliability

Test-Retest
Reliability

6

1-10

5.17

2.22

.91

NA

Tested on 605 subjects with chronic disease
Note: Stanford/Garfield Kaiser Chronic Disease Dissemination Study.
Psychometrics reported in: Lorig et al. (2001) Effect of a self-management
program for patients with chronic disease. Effective Clinical Practice, 4(4),
256-262.

As noted on the Stanford University Chronic Disease Self-Management
program website, this tool as well as all of the other program tools are not
proprietary and have been available at no cost due to funding from the National
Institute of Nursing Research. The instrument contains six items and is selfadministered. The scale uses a Likert-like rating, ranging from 1 - 10, from “not at
all confident” to “totally confident”. Higher scores indicate a higher level of
confidence and, therefore, higher levels of self-efficacy. Reliability coefficients
reported have been .91 for the total instrument (Lorig et al., 2001), but test-retest
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reliability studies have not been conducted on the instrument. Instructions
regarding the use of this specific instrument indicated that it measures only selfefficacy and noted that the scale must be utilized in its entirety. Words and scaling
factors may not be changed or the scale will be invalidated.
At the first class, all leaders provided informational handouts to the
Veterans only, distributed surveys to those willing to participate in the project,
and requested that individuals complete the survey. When surveys were
completed, they were marked at the top of the page with the letter “A”. At the last
class, leaders asked participants if they (a) completed a survey at their first class,
and (b) attended four of the six sessions. If any of the participants had, the leaders
requested these participants to complete another survey. These surveys were
marked at the top of the page with the letter “B”. Pre-addressed envelopes had
been sent to master trainers in advance of their workshops. The surveys were
subsequently returned to the Health Promotion Manager at the Dayton VA.
Aggregate results were to be complied and evaluated to assess differences in
mean scores prior to the workshop and immediately upon completion. Survey data
collection began on April 2, 2013, and continued for six months until October 31,
2013. The survey collection ceased with the IRB closure and results were reported
at that time, on November 15, 2013.
To meet the second objective, whether the program led to a reduction in
subsequent acute care services, data were requested from the Division of Support
Services, located on the Dayton VA Medical Center grounds (see Appendix P).
Specific data elements were identified, including (a) all participants who had
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completed four of the six sessions of the workshop; (b) the number of Healthy U
sessions attended; (c) the number of emergency department visits, the number of
hospital days, and the number of provider visits, all of which would have occurred
during the six months prior to their first Healthy U class; and (d) the number of
emergency department visits, the number of hospital days, and the number of
provider visits during the six months after their last Healthy U class. Dates for
collection of data were January 1, 2012, to December 31, 2013, to allow for a
larger sample size.
Demographics requested were the age, gender, and race of the
participants. The final data requested were the average costs for each of the
identified healthcare services. Aggregate results from utilization of healthcare
services by participants were to be measured six months after the last class and
compared to their utilization of healthcare services in the six months prior to the
first class. T-testing was planned to assess differences, if any, in the mean results
of healthcare services utilization outcomes. These data were to be retrieved from
the Veterans’ electronic medical records and a cost accounting system available at
the VA.
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Project Outcomes
Findings
The outcomes from the study included both descriptive and quantitative
data. Using the same Chronic Disease 6-Item Scale, baseline mean measurement
of perceived self-efficacy compared that of perceived self-efficacy mean
measurement at the conclusion of the workshop. Quantitative data were retrieved
to assess the economic impact of the intervention. Specifically, the number of
emergency visits, hospital days, and provider visits in the six months prior to the
participants’ classes were compared to those that occurred six months after
completion of the classes. These data were to be extrapolated into the costs of
healthcare services and assessed for any differences between the mean costs of the
services prior to the intervention compared to the mean costs after the
intervention.
Data Outcomes and Analysis: Perceived Self-Efficacy
Results were limited in the measurement of perceived self-efficacy. Since
the project did not require participant consent, the questionnaire results were not
paired. Therefore, statistical testing was limited to any observed differences in the
pre and post scores. Statistical significance could not be determined. The
questionnaires had been originally distributed upon approval of all Research and
Approval committees for each VISN 10 facility or clinic site. Collections had
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begun with workshops starting April 2, 2013, through October 31, 2013. Since
subsequent organizational circumstances changed, the original study was closed with
the IRB and survey collection had ceased October, 2013, resulting in smaller samples.
The close-out report provided to the Wright State University IRB included the results
of the surveys (see Appendix M).
The sample consisted of 53 anonymous surveys returned to the principal
investigator. Descriptive statistical testing only was conducted since the results were
not paired. The pre-intervention sample size was 28, and post intervention sample
was 25. The survey process did not allow for identification of participants who may
have either failed to return on the last day of the workshop, or who may have chosen
not to complete a second survey when the second sampling was completed.
Therefore, it was not possible to select initial surveys that should have been
discarded. Descriptive statistics indicated differences in the results measured post
intervention, as noted below:
Table 3
Measurement of Differences in Perceived Self-Efficacy
Timeframe

N

Minimum

Maximum

Mean

Preintervention
Post
intervention

28

2.83

9.50

6.48

25

5.67

10.00

8.20

Note: Dates of collection: April 2, 2013 - October 31, 2013
After completion of the workshops, 28 participants’ mean perceived selfefficacy scores measured 6.48 prior to their workshop sessions and 25 participants
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mean perceived self-efficacy score measured 8.20 after completing at least four of the
six sessions. The pre-survey mean scores were two points lower than the average
mean post-survey scores, indicating a noticeable difference.
Interpretation of findings is consistent with the evidence presented in the
literature review. Although there was no means of determining significance in
perceived self-efficacy measurements by participants after the intervention, as seen
consistently in the evidence, there were obvious differences in scores. Despite the
small sample, the differences in raw scores after the intervention are a clinically
important point to note. For some participants, the intervention may have had some
impact on their beliefs in managing the symptoms of their chronic diseases. If they
believe it did, and it has improved their self-efficacy, they may feel more prepared to
manage their symptoms, be more compliant with their medical regimen and deal
more effectively with the consequences of their chronic disease.
Data Outcomes and Analysis: Healthcare Utilization and Costs
To retrieve data for the health services utilization project objective,
consultation was held with staff of the regional Division of Support Services (DSS).
The Division of Support Services Office was established as part of the Veterans’
Health Affairs Office of Finance. The regional offices have routinely assisted with
data retrieval for research and operations. Staff members extract data from various
databases and from the VA cost accounting system. The data obtained may be
clinical, program, or financial. As previously indicated, the local staff has been
located on the grounds of the Dayton VA Medical Center.
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Specific data elements were identified for inclusion were (a) all Veterans
Healthy U participants from January 1, 2012, through December 31, 2013, from the
five VISN 10 medical centers and any participating clinic sites, (b) the number of
emergency department visits, the number of hospital days, and the number of
provider visits utilized during the six months prior to their first Healthy U class; and
(c) the number of emergency department visits, the number of hospital days, and the
number of provider visits utilized during the six months after their last Healthy U
class. Demographics requested were the age, gender, and race of the participants. The
final data request included the average costs for each of the identified health care
services.
The system produced data by individual participant, from all sites, including
the actual costs per participant for each of the health services utilized during the time
period from six months prior to through six months after completing four of six of
their workshops. In discussion with the VA Privacy Officer, the report was altered to
eliminate any reference to participant’s unique identifier, age, or dates of service
since these data are considered protected by the VA system. The resultant report
included a sample size of 139 participants. The second set of findings that focused on
the healthcare utilization data was entered into SPSS, version 18, and single sample ttests were completed. To avoid Type I error, the level of statistical significance was
adjusted by applying the Bonferroni correction. This was done because the data being
tested were from the same set of data. The level of significance was thus adjusted to
be less than 0.0167 (p<0.0167).
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Results were initially divided into two groups (a) descriptive and (b)
quantitative t-tests. Descriptive results are as indicated in tables four and five.
Table 4
Distribution by Gender

Frequency

Percent

17
122
139

12.2
87.8
100.0

Female
Male
Total

Valid
Percent
12.2
87.8
100.0

Cumulative
Percent
12.2
100.0

Table 5
Distribution by Race

Black or
AfricanAmerican
Declined to
answer
Native
Hawaiian or
other Pacific
Islander
Unsure
White

Frequency

Percent
19.4

Valid
Percent
19.4

Cumulative
Percent
19.4

27

4

2.9

2.9

22.3

2

1.4

1.4

23.7

2
104

1.4
74.8

1.4
74.8

25.2
100.0

As seen in the tables above, participants were primarily white and male,
consistent with the overall utilization pattern seen in the VISN 10 population. The
total sample size of 139 Veterans is less than one hundredth percent of the VISN 10
population who sought healthcare services from January 1, 2012 through December
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31, 2013, which is the period of the program evaluation study (n= .0005). The ages
for both sexes and all races ranged 29-88 years, with a mean age of 62.3 years. This
population was somewhat different than that described previously for those in VISN
10 utilizing healthcare services, in that there were slightly more females (12.2%). The
racial profile was also different, in that there was a higher percentage of Black and
African-Americans in this population (19.4%), about 8% higher than the total
percentage using the healthcare system in the VISN.
Prior to running the paired t-tests, descriptive testing, including displayed
histograms were completed for the dependent means (See Appendices Q, R). The
histogram graphs did not indicate a normal distribution, so additional nonparametric
statistical testing was completed for each of the means comparisons that were
included in those reported (See Appendix S). A review of the results for the paired ttest of the means is noted for each of these quantitative objectives for the project in
tables six and seven.
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Table 6
Paired Sample: Mean Volumes Pre- and Post-Intervention
Volumes

Black or
AfricanAmerican
Declined to
answer
Native
Hawaiian or
other Pacific
Islander
Unsure
White

Frequency

Percent
19.4

Valid
Percent
19.4

Cumulative
Percent
19.4

27

4

2.9

2.9

22.3

2

1.4

1.4

23.7

2
104

1.4
74.8

1.4
74.8

25.2
100.0

*Mean difference calculated by subtracting post value from pre value. Negative values
therefore indicate that the post value was larger than the pre value.
Note: Dates of Collection 1/1/12- 12/31/13
p <.0167

Results from the paired t-tests indicated that there was no statistically
significant reduction in volumes, as measured by these outcomes, for Veterans who
had received healthcare services before and after the workshop.
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Table 7
Paired Sample: Mean Costs Pre- and Post-Intervention
Dates of Collection 1/1/12- 12/31/13

Costs
Project
Objectives

n

6
Hospital
Costs
Emergency 17
Department
Costs
Outpatient 138
Costs

PreRanges

PostRanges

Means
Difference* SD

p

1-72

1-75

-$ 8, 829.5

$ 1,763.9

.125

1-8

1-8

-$ 445.7

$ 1786.7

.309

2-199

1-294

$ 898.5

$ 1,570.0

.503

*Mean difference calculated by subtracting post value from pre value. Negative
values therefore indicate that the post value was larger than the pre value.
Note: Dates of Collection 1/1/12- 12/31/13
p <.0167
Mean hospital days and costs increased but not significantly with mean
increased cost indicating $8,230. Mean emergency department visits and costs also
increased slightly, although also not at a statistically significant rate. The mean dollar
increase ($455.67) was not significant for emergency department visits, since the
mean number of visits increased by less than one visit. Provider outpatient visits
decreased slightly (by nearly two visits) as did costs, but not at a significant rate.
Confidence intervals were somewhat large because of these small sample sizes,
particularly for both hospital and emergency department data.

57

Because the expected assumptions were not met for the dataset, nonparametric
statistical testing was completed for each of the means comparisons were completed
and noted in the table eight.

Table 8
Results of Nonparametric Tests: Paired Sample
Variable
Hospital Days

Hospital Costs

ED Visits

ED Costs

Outpatient Visits

Outpatient Costs

Test
Related samples
Wilcoxon Signed
Rank Test
Related samples
Wilcoxon Signed
Rank Test
Related samples
Wilcoxon Signed
Rank Test
Related samples
Wilcoxon Signed
Rank Test
Related samples
Wilcoxon Signed
Rank Test
Related samples
Wilcoxon Signed
Rank Test

Sig
.102

.116

.871

.730

.061

.035

Note: p<.0167
Results of nonparametric testing affirmed the original results of the paired ttests. There were no significant changes between the pre and post outcomes. Upon
completion of these tests, Cohen’s d was calculated to estimate the effect of the
paired t-test results. Using (a) .2 to indicate small effect, (b) .5 as medium effect, and
(c) .8 for large effect, the estimated effect of the intervention on mean costs for each
acute care service was noted as indicated in the table below. Inpatient costs may have
not have increased significantly, but the effect was perceived to be large. The effect
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on both increased emergency and outpatient costs was noted to be small, as were the
means cost differences.
Table 9
Paired Sample: Estimation of Effect: Differences in Costs
Cohen’s d

Effect size

Inpatient Costs

7.2

Large

Emergency Department Costs

.2

Small

Outpatient Provider Costs

.2

Small

Service

Note: Cronk, B. How to use SPSS: A step by step guide to analysis and
(2008).

interpretation

Independent t-testing was then completed on the entire sample.
Documentation of histograms again indicated lack of normal distribution (See
Appendix T) .The results of the independent t-test s of means for the entire sample
are noted in tables ten and eleven.
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Table 10
Total Sample Mean Volumes Pre- and Post-Intervention
Volumes
Project
Objectives

Pre n

20
Hospital
Days
Emergency 38
Department
Visits
Outpatient 139
Visits

Post n

Pre Mean

Post Mean

15

8.4

31

138

Post SD

14.93

Pre
SD
16.22

2.24

2.68

1.80

2.48

42.88

41.88

34.67

40.36

22.21

Note: Dates of Collection 1/1/12- 12/31/13

Table 11
Total Sample Mean Costs: Pre- and Post-Intervention
Costs
Project
Objectives

Pre n

20
Hospital
Costs
Emergency 38
Department
Costs
Outpatient 139
Costs

Post n

Pre Mean

Post Mean

Pre SD

Post SD

15

$33,788

$43,683

$4,933

$8,864

31

$1,060

$1419

$912

$1,554

138

$17,619

$18,845

$16,907 $19,451

Note: Dates of Collection 1/1/12- 12/31/13
Results of the independent sample t-tests were then analyzed with the
Mann-Whitney test since the data lacked normal distribution. Results are included in
table 12.
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Table 12
Mann-Whitney Nonparametric Testing

Project
Objectives

Pre n

20
Hospital
Costs
Emergency 38
Department
Costs
Outpatient 139
Costs

Post n

Pre Mean

Post Mean

Pre SD

Post SD

15

$33,788

$43,683

$4,933

$8,864

31

$1,060

$1419

$912

$1,554

138

$17,619

$18,845

$16,907 $19,451

Note: p< 0.0167
Once again the results indicate no significant difference in the utilization of
healthcare services by the Veterans in entire sample (139 participants), six months
after the workshop. The results for the participant group was consistent with the
paired samples in that no significant difference was perceived in the utilization of
acute care health services in the six -month period following their workshop. Fewer
participants utilized acute care services. However, the costs of those services were
higher, primarily due to an increase in hospital days and/or possibly an increase in
resources utilization during the hospital stay. Little cost increase was observed in
outpatient visits, and, despite fewer individuals utilizing the emergency department,
a small increase in costs was also observed.
Six months after the intervention these documented healthcare utilization
outcomes indicated results mirroring some of those noted in the evidence (Foster et
al., 2009; Kennedy et al., 2007; Lorig et al., 2003). The described evidence included
studies in which six months after intervention, emergency department visits were
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reduced, but hospital days were not affected. Mean outpatient visits were often
decreased, but not at a statistically significant level (Brady et al., 2013; Lorig et al.,
2001; Lorig et al., 2003; Whitelaw et al., 2013).
Step V Justify the Conclusions
This evaluation was conducted to assess the impact of the Healthy U program
known as Chronic Disease Self-Management Program in VISN 10. The original
intent had been to determine the effect on the participants’ perceived self-efficacy
after completion of the workshop and to determine if the intervention affected their
utilization of healthcare services six months after completion of the intervention, as
compared to their utilization six months prior to the intervention. At the outset of the
project data requested had included more specific information about the participants
including the presence of specific co-morbidities identified to be the most frequent
among the Veteran population including: (a) diabetes, (b) heart disease, (c)
hypertension, (d) depression, and (e) arthritis (Hoerster et al., 2012). Also requested
had been the percentages of Veterans who had one of these diseases and those who
had three or more of these diseases. These data had been requested so that that there
might be the possibility of ascertaining a relationship between participants with comorbidities and their utilization of healthcare services. With the revisions in the study
necessitated by organizational circumstances and processes, these data were not
available at that time.
Veterans who utilize the VA system, as previously discussed, generally mirror
the needs of the aging population with chronic disease in the country (Petersen et al.,
2010). Three of the diseases that precipitated the highest rates of hospital admissions
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were among the co-morbidities found in the Veteran population (Hoerster et al., 2012;
Squires, 2011). Veterans over the age of 65 years have reported having more chronic
diseases and poorer health than non-Veterans (Hoerster et al., 2012). Studies have
indicated that increases in healthcare costs are noted with additional chronic
conditions (Lehnert et al., 2011; Machlin & Soni, 2013).
If the data regarding the prevalence of these chronic diseases among this study
population had been available, they might have assisted in the evaluation of the
utilization of healthcare services among this population, particularly hospital days. A
review of the raw data indicated wide variation, with a few participants requiring
significant hospital days. Participants with several chronic diseases or in later stages
of their disease certainly would have required a greater intensity of resources with
resultant increases in costs.
In this step (justify the conclusions) of the framework for program evaluation,
an evaluation of the standards provided as guidelines to be utilized during the process
should be included. There were four standards within the program evaluation
framework that were initially identified in the report: (a) utility, (b) feasibility, (c)
propriety, and (d) accuracy.
The utility standard was noted as necessary to assure the needs of the user are
met. The quantifiable project objectives were specifically designed to address two
purposes, to meet the requirements for completion of an academic degree and to lay
the foundation for routine reporting of outcomes for the Healthy U program.
Although limitations to the study have been identified, ongoing reporting of program
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outcomes is expected. There may be opportunities for improvement but this standard
for program evaluation has been satisfied.
Despite barriers throughout the process, the program evaluation design
eventually was identified to be reasonable. A framework for program evaluation was
selected and determined to appropriate to meet the standard for feasibility.
During the evaluation process, consultation was held with the Research and
Development staff at the VISN 10 centers to follow all appropriate procedures to
assure and protect the rights and privacy of the Veterans involved. These steps were
taken to assure compliance with propriety standards within the program evaluation
framework.
Great care and attention to detail was paid to assure accuracy in requesting,
clarifying, reporting, displaying, interpreting, and analyzing these program data.
Clarification was sought when duplication of data elements, specifically racial
identification, occurred in the data report. Since participants update their information,
staff at the DSS center indicated that original data may not be removed from the
system. Therefore, when racial identity was missing duplicate data without racial
identification was removed from the database. Participants who did not complete at
least four of the six sessions were also removed from the study database. These
individuals were identified by the number of notes made by the Healthy U leaders in
their records and pulled into the report by the electronic system. Findings have been
carefully reviewed in the context of accepted statistical procedures to avoid error and
misinterpretations as well as to identify limitations to meet expectations for the
accuracy standard (McKenzie et al., 2009).
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Study Limitations
There are several limitations to this study. Because informed consent was not
obtained, the survey utilized to measure perceived self-efficacy was not a paired
sample and no statistical testing was completed. Participants were volunteers for the
interventions, which might have influenced the results, particularly for the surveys.
There is indication that some participants attended more than one workshop which
might have influenced outcomes as well.
Participant data obtained for healthcare utilization were not randomized but
received from all sites and in whatever order they were pulled from the listing of
codes entered by DSS staff. Duplicate descriptive data received from the DSS staff
and noted in the report regarding race were deleted based on information obtained
from staff that follow-up registrations subsequently corrected omitted or inaccurate
data elements. Data obtained were limited, in that no specific information was
available about participants. There are no data known or available on their specific
chronic disease, their medical plan of care, or any support systems that may have
affected their compliance to self-management regimen. This may be significant
because any additional data regarding participants’ health and/or the state of their
chronic diseases may have been very useful in the assessment of utilization of acute
care services.
Although the cost for services has been calculated for the services provided
through the VA cost accounting systems, the specific methodology utilized has not be
identified or explained, so the calculations and results cannot be clearly explained or
verified.
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The paired sample sizes for both inpatient care and emergency department
visits drawn from the total population size (139), were small, six and 17 participants,
respectively. The total sample size of 139 Veterans, represents a small contingent of
those who sought services from the health care centers in VISN 10 from January
2012 through December 2013..Given these small sample sizes and wide variation in
results , preliminary conclusions cannot be drawn at this time, , without the possibility
of error. The timeframe (six months) within which outcomes were assessed is
relatively short; research studies have recommended longer periods of time or
sequential periods of time for ongoing measurement of these same outcomes.
Step VI Ensure Use with Lessons Learned
Project findings were summarized and reported to the principal investigator. A
report will be prepared for the VISN leadership, the major stakeholders, who
approved the program and its expenditures. The report will also be shared with the
master trainers who provided so much support to the study. Plans are to continue to
add to the database and monitor these same outcomes to assess impact of the program
on its participants and its contribution to VISN 10.As the Healthy U program
continues to expand within VISN 10 and additional participant data are added,
seeking additional data regarding participants’ health, the number and the state of
their chronic diseases may be helpful in the assessment of utilization of acute care
services. These data could be useful in predicting service needs, utilization, and
resource allocation within the VA system in general and VISN 10 in particular.
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Recommendations
There are already plans for continuing data collection for the Healthy U
program to assess its effect on its potential economic outcomes. The investment
made by the VISN requires careful evaluation of the resources already deployed.
Continued study of the results from the program evaluation data may assist in
planning for future program needs in the management of chronic disease among
the Veteran population. Additional recommendations for consideration might
include maintenance of the participant data base so that additional meaningful
data can be managed, monitored and reported. Data should be maintained and
analyzed annually, at a minimum, and at time intervals, 12 months, 18 months
and 24 months, to assess improvement and/or retention of benefit for the
participants. Data collected should include continued measurement of the means
for acute care days, emergency department visits, and provider visits prior to and
after the identified time period.
Mean cost data should also be included in the ongoing data collection, but
there should be ongoing dialogue with the DSS staff to assure that the
methodology for ascertaining cost does not change from one data collection
period to the next, in order to assure consistency in interpretation of results.
In addition to the data analyses already described, the master trainers
should consider using some of the other tools available to them from Stanford
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University that will allow the assessment of perceived clinical outcomes, such
pain or mobility. Measurement of clinical results such as AIc or tidal volumes
may also be outcomes of interest for selected populations or clinics.
Feedback from veterans regarding their ability to manage their chronic
disease is an important outcome from self-management programs. Ongoing
measurement of perceived self-efficacy with the use of paired samples is
recommended to determine to assess if differences exist prior to the intervention
and afterwards. Feedback from Veterans about this program and what they
perceive they have learned or experienced is important to provide to the VISN. To
receive meaningful feedback regarding perceived self-efficacy, the survey must
be paired. This will require some means of identifying the participants. The
master trainers will need to ascertain if this effort may require authorization from
their IRBs and informed consent, since informed consent will also require those
obtaining it to complete Citi training required by the VA.
Meaningful data regarding the Veterans’ perception of the program is
necessary and should be collected in an appropriate manner. For this reason,
narrative feedback from the participants may be both useful and clinically
significant. Qualitative data may allow themes to be extracted from either
interview with participants or written comments. The data supplied can be shared
with the decision-makers to provide insight into what the participants believe they
have achieved from the program.
In summary, the sample for this project is so small, the confidence
intervals so imprecise, and differences and effect relatively small, with the
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exception of the inpatient costs. The inpatient sample, however, is also small and
inpatient costs may vary widely, depending on the participants’ healthcare
problems or needs. Consequently, it would be premature to evaluate the Healthy
U program based on these findings. Instead, it is more important to continue to
collect data and amass a larger sample to assess the program’s continuing impact
on the Veteran population in VISN 10.

69

Conclusion
The prevalence and burden of chronic disease in the U.S. is continuing to
grow and place heavy demands on the entire healthcare system (Anderson &
Horvath, 2004). The number of individuals with chronic disease increases with
the aging population. With the advancement of medical technology, the
population is living longer and requiring care longer in life. With the increase in
the number of individuals needing care, as well as the increase in services they
demand or require, healthcare costs will continue to drive government, private
payers, and individual’s financial responsibilities upward. Despite the decreasing
number of Veterans, these same demographic factors are affecting Veterans’
healthcare services. The burden of resulting costs is being exacerbated by
Veterans with one or more chronic diseases.
Chronic disease self-management programs are among the few alternative
models of care that can create value for participants by increasing their confidence
in managing their health problems and reducing cost so that limited resources can
be used more effectively. These programs shift the focus from the old
authoritarian provider model of simply adhering to medical guidance to learning
the knowledge and skills they need to “incorporate the psychological and social
management of living with a chronic illness” (Newman, Steed, & Mulligan, 2004,
p. 1523).
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Appendix A
Centers for Disease Control Framework for Program Evaluation

STANDARDS
Utility
Feasibility
Propriety
Accuracy

Note: McKenzie et al., 2009, p. 34

82

Appendix B
Workshop Overview
Week
1

Week
2

Week
3

Week
4

Week
5

Week
6

Overview of self-management
and chronic health conditions

•

Making an action plan

•

•

•

•

•

•

Using your mind to manage
symptoms

•

•

•

•

•

•

Feedback/problem-solving

•

•

•

•

•

Difficult Emotions

•

Fitness/exercise

•

•

Better breathing

•

Pain

•

Fatigue

•

Nutrition

•

Future plans for health care

•

Communication

•

Medications

•

Making treatment decisions

•

Depression
Working with your health care
professional
Working with the health care
system
Future plans

•
•
•
•

Note: CDSMP T-T Manual Appendix 1 2010; Chart Summary, p. 3.
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Appendix C
United States Preventative Services Task Force: Hierarchy of Research Design

I

Evidence obtained from at least one properly-designed randomized
controlled trial

II-1

Evidence obtained from well-designed trials without randomization

II-2

Evidence obtained from well-designed cohort or case controlled analytic
studies, preferably from more than one center or research group

II-3

Evidence obtained from multiple time series with or without the
intervention. Dramatic results in uncontrolled experiments (such as the
results of the introduction of penicillin treatment in the 1940’s) could also be
regarded as this type of evidence

III

Opinions of respected authorities, based on clinical experience, descriptive
studies, or reports of expert committees

Note: United State Library of Medicine, National Institutes of Health, U.S. Preventive
Services Task Force: Appraising the evidence. 2008
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Appendix D
Institutional Review Board and Study Approval Processes
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Appendix E
Study Protocol

Study Summary
This study will evaluate the impact of the Stanford University Chronic Disease SelfManagement Program (CDSMP) on volunteer participants. This licensed and scripted
program, developed by Stanford University, consists of a series of six weekly sessions
conducted by two trained lay leaders and/or healthcare professionals. During these
sessions, participants learn strategies for dealing with chronic conditions, practice selfmanagement skills, and provide/receive peer support for their efforts. Researchers at
Stanford University and other sites have documented program outcomes that include
decreased disease symptoms, increased self-efficacy, and decreased utilization of
healthcare resources.
All VISN 10 VA facilities implemented the program in FY12 and plan to expand it in FY
13. Because there are limited data about outcomes for the CDSMP among Veterans, this
evaluation is being done to assess the effect of the program in VISN 10.
Background and Significance
The prevalence of chronic diseases is rising. In 2005, nearly 133 million Americans had
at least one chronic disease. By 2020, that number is anticipated to increase by 16% to
150 million or more. Many Veterans have more than one chronic illness. Symptoms of
chronic illnesses - including pain, fatigue, muscle tension, shortness of breath, and
depression - can be debilitating and interfere with normal life activities. Although
medical treatments and medications are crucial in the management of chronic disease,
disease outcomes are heavily impacted by the decisions that patients make every day
about physical activity, food intake, stress management, and adhering to a medical plan
of care.
Individuals with chronic conditions consume a lot of healthcare resources, and they have
been found to utilize more services, at greater expense, as the numbers of their chronic
conditions multiply. Much of the growth in health care spending is related to the care of
individuals with chronic conditions.
There are few studies specific to prevalence of chronic disease in Veterans using the VA
system, but the chronic disease burden is estimated to be similar if not greater than the
general population. Utilization of healthcare services and costs of care for Veterans
increases with the number of identified chronic conditions.
The CDSMP is one of several self-management programs have been designed to help
patients make healthy decisions, manage symptoms using self-care strategies, work with
their healthcare team, and use the healthcare system more efficiently. Approaches like
these, if effective, could help contain or reduce costs, and also improve the quality of life
for those with chronic diseases. The Chronic Disease Self-Management Program was
developed in 1996 by Stanford University with a grant from Agency for Healthcare
Research and Quality.
Method of Subject Identification and Recruitment
Individuals, male or female who have signed up to participate in the Chronic Disease
Self-Management Program (known as Healthy U) at the Dayton Veterans Affairs
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Medical Center over a period of six months will be invited to participate in evaluating the
program. The invitation will be written in a handout describing the program evaluation
process and containing the pre-program assessment survey Individuals, male or female
who have signed up to participate in the Chronic Disease Self-Management Program
(known as Healthy U) at the Dayton Veterans Medical Center during a six-month period
of study will be included in the program evaluation. Although class participants may
include Veterans and non-Veteran family members, only Veterans will be asked to
complete surveys before and after the program. Both male and female Veterans will be
recruited for participation. It is estimated that 60 Veterans will be recruited in the six
month period.
Inclusion Criteria
Subjects must
o Be Veterans
o Be 21 years or older
o Signify willingness to participate in the evaluation by completing the survey
o Complete the program by attending at least four of six sessions of a workshop
within the six-month study period
Exclusion Criteria
 Chronic Disease Self-Management Program participants not meeting the inclusion
criteria
Data for Veterans who do not complete the survey will be excluded by removal from the
list of participants that is provided to the Division of Support Services for data collection
by means of encrypted e-mail.
Study Design and Methods
This protocol describes a program evaluation process focused on 1) a self-report of selfefficacy before and after the CDSMP workshop, and 2) a comparison of utilization of
healthcare resources in the six-month period before the workshop and the six-month
period after the workshop. Self-efficacy was chosen as an outcome variable to determine
if the participants experienced an increase in their confidence in managing their chronic
conditions after completion of the program. Healthcare utilization data were selected as
outcomes to determine whether the program was associated with cost reductions. Data
about each participant will be extracted from electronic patient records and provided in a
report to the researchers without any patient-identifiable information. These demographic
variables will be reported to describe the participants:
•
age
•
sex
•
marital status
•
VA medical center where the course was provided
•
presence and documentation by ICD-9 code of any of the following at the
time of hospital discharge: hypertension, diabetes, heart disease, depression,
and arthritis.
Outcome variables were selected to assess the impact of the program on the participants’
perceived self-efficacy, which is the confidence to manage their chronic disease, and an
87

outcome determined to be related to successful self-management programs. Utilization of
healthcare was chosen because there is interest in determining if this alternative model of
care for the Veteran population might result in cost reductions, preserving resources for
the provision of other programs and services.
The measurements of self-efficacy will be done using the six-item Chronic Disease Self Efficacy Scale (attached). This scale was developed and tested by Stanford University
(internal consistency reliability of 0.91). The Stanford University website grants
permission for use of this tool. Program leaders will provide the tool to Veteran
participants at the first class and at the completion of the final class; participants' names
will not be attached to the surveys. Mean scores will be calculated for the two survey
points, using a test-retest design for the mean. The willingness of the participants to
complete the tool will be assumed to be their consent.
Aggregate results from utilization of healthcare services by the participants will be
measured six months after the last class and compared to their utilization of healthcare
services in the six months prior to the first class. Healthcare utilization data will be
obtained from a report generated by Division of Support Services without any patient
identifiable information:
 numbers of visits to emergency departments or urgent care centers within the
Veterans medical centers in the six month period before the first Chronic Disease
Self- Management Program session
 numbers of visits to emergency departments or urgent care centers within the
Veterans medical centers in the six month period after the last Chronic Disease
Self- Management Program session
 number of hospital days in the six month period before the first Chronic Disease
Self- Management program session
 number of hospital days in the six month period after the last Chronic Disease
Self- Management Program session
 number of number of visits to outpatient healthcare providers in the six month
period before the first Chronic Disease Self- Management Program session
 number of visits to outpatient healthcare providers in the six month period after
the last C Chronic Disease Self- Management Program session
Pooled results of the means of utilization of healthcare services by the participants will be
measured six months after the last class and compared to their utilization of healthcare
services in the six months prior to the first class. Lists of participants who have agreed to
be included in the study will be provided to the Division of Support Services by means of
encrypted e-mail. Data for participants electing not to participate will be excluded by
removal from this list of participants that is provided to the Division of Support Services.
Data will then be extracted from the electronic record by the Division of Support Services
and provided to the investigators in a table that will display the demographic variables,
including age, gender, marital status, and chronic conditions. No personally identifiable
data will be displayed. Consequently, no personal health or identifiable information will
be connected to the participants. To track the number of subject records collected, the
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Subject number column in the data collection tool will be numbered from 1 to the end of
the data collected.
Risks: Risks to patients in this study will be minimal as no active interventions are
proposed and study data will be pre-existing. The main risk of this study would be patient
confidentiality. However, every effort will be made to study data in a confidential
manner. All data will be stored on a password protected computer in a secure location
with limited access only to the study staff in the locked office on medical center
premises. Risk would be added if consent were to be obtained; copies would need to be
maintained.
Benefits: There are no direct benefits to the participants in this study. The benefits to be
clarified are cost benefits. However, the additional benefits of doing this study is to assess
potential program outcomes for a health oriented intervention that is patient-centered
empowering the patient to assume responsibility for managing his or her health and
chronic conditions.
Data Analysis and Data Monitoring
Perceived self-efficacy outcomes will be measured by statistical testing using t-tests of
the means. Data will be aggregated by measuring the means of all scores from the
questionnaire pre-tests and compared to the means of all scores for the questionnaire
post-test. For healthcare services utilization outcomes, repeated single analyses of
variance will be used to compare the mean participant emergency department utilization,
hospital bed days, and provider visits six months prior to the first class of the program
and six months after the completion of the program.

We are so glad you have joined us for our
classes and hope you are looking forward to the next six weeks.
You should learn a lot about living with health problems. We are doing a
study to see what difference this course can make in Veterans’ health. So we
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are asking you to fill out a survey on the first day and another one on the last
day. The survey is the only difference in the course. After your course has
ended, we will use information from your electronic record to learn about
your health.
Please do not write your name on the survey.
You do not have to take the survey. Just tell you course leader and your
information will not be used in the study. Your Healthy U course will be the
same either way.
Thank you!
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Self-Efficacy for Managing Chronic Disease
6-Item Scale
We would like to know how confident you are in doing certain activities. For each of the
following questions, please choose the number that corresponds to your confidence that you
can do the tasks regularly at the present time.
Not at all confident

1

2

3

4

5

6

7

8

9

10

Totally confident

1. How confident are you that you can keep the fatigue caused by your disease from
interfering with the things you want to do?
1

2

3

4

5

6

7

8

9

10

2. How confident are you that you can keep the physical discomfort or pain of your disease
from interfering with the things you want to do?
1

2

3

4

5

6

7

8

9

10

3. How confident are you that you can keep the emotional distress caused by your disease
from interfering with the things you want to do?
1

2

3

4

5

6

7

8

9

10

4. How confident are you that you can keep any other symptoms or health problems you
have from interfering with the things you want to do?
1

2

3

4

5

6

7

8

9

10

5. How confident are you that you can do the different tasks and activities needed to
manage your health condition so as to reduce you need to see a doctor?
1

2

3

4

5

6

7

8

9

10

6. How confident are you that you can do things other than just taking medication to reduce
how much you illness affects your everyday life?
1

2

3

4

915

6

7

8

9

10
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Louis Stokes Cleveland Department of Veterans Affairs Medical Center
Request for EXEMPTION from IRB Review
Please s ubmit this completed form to the IRB and when accessing or collecting id entifiers submit a
HIPAA W a iver Request. Please contact the IRB office if you have any questions at (216) 791-3800 ext.
4658.

EXEMPT research incl~des research activities in which the only involvem ent of human subjects is
in one or more of the categories listed in Section 3 (38 CFR 16. lOl (b) .) The exemp t status must be
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1. Date: 2/11 /13
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March 2011

Signature ofIRB Chairperson or Designee

Date

NOTE: AU research must be reviewed and approved by the Research & Development
Committee, prior to initiating any study activities. Contact R&D Committee Coordinator
at x3646.
You must notify the IRB office if your research changes after approval because the exemption may 110 longer
apply. Please refer to the LSCDVAMC Human Research Protection Program Staodard Operating Procedures for
additional information and examples ofwhat qualifies as exempt research. (See also VHA Handbook 1200.05; 38
CFR 16. IOJ(b); 45 CFR 46. IOJ(b))
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Appendix I
Revised Petition
Petition for Approval of Research Involving Human Subjects
Office of Research and Sponsored Programs (RSP)
201J University Hall
Wright State University
Dayton, OH 45435
(937) 775-2425 – Voice / (937) 775- 3781 - Facsimile
The attached petition is to be used when requesting review for approval of research
protocols involving human subjects by the Wright State University Institutional Review
Board (IRB). This petition is to be used for either full board or expedited (Expedited
Review Advisory Committee) review. A separate form is used for submitting
amendments to approved protocols. This form, which includes instructions for use, can
be found on the RSP web site (www.wright.edu/rsp/subjects.html).

The information requested in this petition is necessary and must be on file for inspection by
authorized individuals. Therefore, the appropriate Board/Committee cannot review this petition
unless all the questions have been adequately addressed. When submitting your application, follow
the INSTRUCTIONS below.
The information in this petition may become publicly available either through the Ohio Open
Records Act or through open meetings. For additional information, see the signature page.

INSTRUCTIONS
Review by the Full Institutional Review Board:
Research activity involving more than minimal risk to the subject (see
http://ohrp.osophs.dhhs.gov/humansubjects/guidance/45cfr46.htm#46.102 for definition of minimal risk)
must be reviewed by the full Institutional Review Board (IRB). If this project falls under full board review,
submit 24 collated copies of the completed petition and all supporting documents (one copy must contain
original signatures of principal investigator, co-investigator(s) and, for a student PI, the faculty
advisor). Supporting documents may include: 1-2 page summary, consent form(s), cover letter(s), agency
permission documents, questionnaires, interviews, debriefing material, advertisements, etc. In addition,
submit 4 copies of the complete research protocol, 1electronic copy (PDF) of the complete research
protocol (sent to Robyn.Wilks@wright.edu),4 copies of the PI’s CV (and CV of faculty advisor for
students), 2 copies of the grant proposal (if applicable) and 4 copies of the investigator’s brochure (if
applicable). If this is a funded study and the sponsor (incl. DHHS/NIH) has approved the human subjects
protocol and consent form, submit one copy of these documents as approved. Do not include the
instruction page with your submission. Submit all documents to the Institutional Review Board, c/o RSP.

Expedited Review:
Research activity involving no more than minimal risk to the subject (see
http://ohrp.osophs.dhhs.gov/humansubjects/guidance/45cfr46.htm#46.102 for definition of minimal risk)
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may be eligible for expedited review. If this project falls under expedited review, submit 10 collated copies
(1 single-sided original and 9 double-sided copies) of the completed petition, CV of PI (and faculty advisor
for students) and all supporting documents (one copyof the petitionmust contain original signatures of
principal investigator, co-investigator(s) and, for a student PI, the faculty advisor). Supporting documents
may include: summary (max of 4 double-spaced pages), consent form(s), cover letter(s), agency permission
documents, questionnaires, interviews, debriefing material, advertisements, etc. Do not include the
instruction page with your submission. In addition, submit 1 copy of the research protocol, if available.
Submit all documents to the Expedited Review Advisory Committee, c/o RSP.

Exempt Research:
Eligibility of protocols for exemption under current NIH guidelines (see the six items in paragraph b. of
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm#46.101) is determined by the IRB Chair.
To request an exemption for your project, complete the petition and submit 1 copy of the appropriate
documents as described under Expedited Review by the Expedited Review Advisory Committee.

Please TYPE and SIGN before submitting. Copies should be individually stapled,
clipped or banded, with no covers.If you have any questions concerning the petition or
meeting dates, please contact the IRB Coordinator at 775-4462.
Note: Deadline dates for submission of petitions to RSP may be found on the
human subjects web page at: http://www.wright.edu/rsp/subjects.html
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Petition for Approval of Research Involving Human Subjects
Wright State University Office of Research and Sponsored Programs
Date: 12/31/12

For RSP use only
IRB Assignment Number: _________________________

Title of Research Project: An Evaluation of the Chronic Disease Self-Management Program
Requested Review Assignment (NOTE: Research and Sponsored Programs will determine the actual
review designation. Therefore, you may be required to provide additional copies)
Full Board Review
X Expedited Review [see http://www.hhs.gov/ohrp/policy/expedited98.html]
Exempt Research [see
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html#46.101]*
*you must provide the appropriate citation for this exemption request:
PRINCIPAL INVESTIGATOR INFORMATION:
Principal Investigator
Beth Cameron

Academic Title

Phone
937-268-6511

Department
Health Promotion

Fax

Address
4100 W 3rd St Dayton, OH 45428,

E-mail
Beth.Cameron@va.gov

Contact person to receive study correspondence. Include name &
phone no.
Beth Cameron – 268-6511, ext 2527

Contact E-mail
Beth.Cameron@va.gov

Position (check one):
Faculty:

Student/Resident:

Staff X

Other (specify):

Indicate the names of other investigators participating in the research. If a student is listed as principal
investigator, specify a faculty advisor. If study-related healthcare decisions are to be made and the PI does
not have a license to practice medicine in Ohio, a qualified clinician must be listed. Indicate academic
titles, if any, for all investigators.
Joan Sevy Majers , MS, RN, WSU doctoral student

(WSU only) Check here to indicate that Principal Investigators/Advisor (exempt protocols)or all
investigators/advisor(expedited and full board) have completed the required human subjects protection
training offered by Collaborative Institutional Training Initiative (CITI)through Wright State
University—see http://www.citiprogram.org/ and IRB Policy P.5. (found in the IRB Charter at
http://www.wright.edu/rsp/IRB/irb_charter.html).
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X(Other institutions) Check here to indicate that Principal Investigators/Advisor (exempt protocols)or all
investigators/advisor(expedited and full board) have completed the required human subjects protection
training offered by Collaborative Institutional Training Initiative (CITI)through another institution.
Please attach a copy of the CITI report for each investigator listed on the study.
FUNDING INFORMATION:
Indicate the category of the sponsor (if applicable):
State Government
Industry (other than pharmaceutical)
Pharmaceutical Company
Non-Profit Organization
Internal Grant Program
X No Funding

Local Government
Federal Agency

Other (specify)

INVESTIGATOR POTENTIAL FINANCIAL CONFLICT(s) OF INTEREST:
1.

Does the investigator or co-investigator(s) have a vested interest in any actual or potential
commercial enterprise/business associated with any aspect of this protocol (other than patents)?
Yes

X No

If yes, fully explain and identify the safeguards taken to prevent investigator bias in subject
recruitment and/or the consent process:
2.

Are there financial issues that may be of concern to potential subjects? If no, please certify this
for all investigators by checking the following boxes to indicate that the investigator(s):
X Does not have ownership interest, stock options or other financial interest related to the
research whose value, when aggregated for immediate family, represents >5% interest in any one
single entity
X Will not receive compensation related to the research whose amount is affected by the outcome
of the research
X Has no equity interests in the sponsor of this study greater than $10,000 (when aggregated for
the immediate family), or does not have ownership interest, stock options, or other financial
interest related to the research of any value whose value could not be determined through
reference to publicly available prices
X Does not have Board or executive relationship related to the research, regardless of
compensation
X Is/are receiving no payments by the sponsor greater than $10,000 to the investigator’s
performing organization(s) exclusive of the costs of conducting the study
X Will receive no payments by the sponsor directly to the investigator(s), their spouses or
dependent children
X Has no financial interests (other than patents) in any non-sponsored research
If all boxes above cannot be checked, please describe below (or in a separate attachment) how
such financial arrangements will not adversely affect the interests of the research subjects, and
how subjects will be given any information which may be material to potential subjects’ decisionmaking process.
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PROTOCOL INFORMATION
Attach a concise description summarizing the following areas (specifically address the subject’s role in the
research). This will be provided to all IRB members for review. [Note: for expedited or exempt review
protocols, submit a MAXIMUM of 4 double-spaced pages; descriptions exceeding this limitation will
be returned for re-writing.]








Purpose of research
Background and hypothesis
Procedures
Risks
Potential benefits
Inclusion and exclusion criteria
For all DHHS studies, a copy of the DHHS-approved sample consent document and the
complete DHHS protocol must be submitted.
In addition, provide (1) copy of all documents to be given to subjects during the research.
Please answer the following questions about the protocol:
3. Indicate all that apply to the research:
Investigational new drug

FDA approved drug being used for unapproved

use
FDA approved drugs
Humanitarian use device
Investigational new device
Gene therapy
X Chart review*
Telephone interview
Retrospective study**

FDA approved drug – new route of administration
FDA approved drug – new formulation
Tissue banking
New drug delivery system
In-person interview**
X Self-administered questionnaire**
Public dataset without identifiers***

Other (describe)
*Note: For chart reviews or retrospective studies, copies of the data collection instruments must be
provided. **Copies (see instructions for number) of any interview, surveys, or questionnaires must
be submitted along with documentation that permission has been obtained to use any copyrighted
materials in your research. X Please check here to indicate that appropriate permission has been
obtained. ***For public datasets without identifiers, a copy of the data review form must be
provided.
4. Does the research involve a drug or device for which an investigational new drug (IND) or
investigational device exemption (IDE) has been filed?
Yes
X No
If yes,
Provide the IND or IDE number:
Who holds the IND or IDE?
Please provide documentation verifying the IND or IDE number, such as a letter from the
sponsor or a copy of FDA correspondence.
If no and the research involves the use of drugs or devices, please answer the following
questions
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Device Studies
Yes
No
Yes
No
health, safety
or welfare of a subject?

Is the device intended as an implant?
Does the device present a potential for serious risk to the

Drug Studies
Yes
No
Will study results be reported to the FDA in support of a new
indication for use; OR to support any other significant change in the
labeling of the drug(s); OR to support a significant change in the
advertising for the product(s)?
Yes
No
Will the study involve a route of administration, dosage level,
use in a
patient population or other factor that significantly increases the risks
(or decreases the acceptability of the risks) associated with the
drug
product?
Please list all study drugs or devices by generic name only (if no name, list sponsor’s study drug number)
FDA Approved for any
FDA Approved for this
Is the drug being
indication?
indication?
compared to placebo?
Yes
No
Yes
No
Yes
No
1.
2.

Yes

No

Yes

No

Yes

No

3.

Yes

No

Yes

No

Yes

No

4.

Yes

No

Yes

No

Yes

No

5.

Yes

No

Yes

No

Yes

No

6.

Yes

No

Yes

No

Yes

No

RISK ASSESSMENT:
5. Does the study involve any risk to the subjects? Examples of risks/discomforts include: dizziness,
nausea, embarrassment, social stigma (shame or disgrace), psychological distress, loss of employment,
invasion of privacy and breach of confidentiality.
Yes X No
If yes:
a.
b.
c.

Indicate where these risks are described in the protocol and consent form/cover letter.
Are the risks/discomforts reasonable in relation to anticipated benefits (if any)?
Yes
No
Indicate how risks to subjects have been minimized where possible. For example:
Subjects have received 24-hour emergency phone numbers
More frequent health exams or diagnostic tests are being performed to monitor for known
or
anticipated risks
Emergency equipment is available for use if needed
Specimens/samples already collected for standard treatment are used for research
purposes
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whenever possible
Other (please specify)

SAFETY MONITORING:
A plan for data safety monitoring should be provided in any situation in which participants might be at
greater than minimal risk of harm, including when a drug or device is being tested for safety or
effectiveness for marketing approval, or in placebo-controlled trials, or when marketing drugs are being
tested for another indication or compared for safety or effectiveness. A plan is required for all clinical
trials, including the development or evaluation of clinical laboratory tests (e.g. imaging or diagnostic tests)
if the test will be used for medical decision-making for the subject, or if the test itself imposes more than
minimal risk for subjects. Guidelines regarding drafting this plan can be found in Part II, Supplemental
Instructions for Preparing the Human Subjects Section of the Research Plan, of the U.S. Department of
Health and Human Services Public Health Service Grant Application (PHS 398) instructions at <
http://grants.nih.gov/grants/forms.htm>.
6. Does the protocol require a safety data monitoring plan?

Yes X No. If yes:



Indicate where the description may be located within the protocol



If not described within the protocol, attach a copy of the plan. Copy attached?



If there is no plan, please explain why there isn’t one.

Yes

No

7. When applicable, will medical or psychological resources be made available to participants after their
completion of the study, if the research produces consequences in which these services are required?
Yes
No x N/A. If yes:


Indicate where the description may be located within the protocol:



If not described in the protocol, attach an explanation of resources. Explanation attached?
No



If there are no resources, please explain why there aren’t any.

Yes

CONFIDENTIALITY AND PRIVACY:
8.

Indicate the procedure for assuring confidentiality of the data (e.g. responses kept in locked safe,
restricted access to information, etc.) or for assuring the anonymity of the subjects (e.g. no names on
instrument, no personal identifiers linked to instrument, any in-person interviews/videos, etc.) Please
note that student investigators must store study records or data in a Wright State location (i.e. not at
home).

Paper survey to be utilized will not contain any names or personal or protected information. Reports
produced from the electronic file by the VA Division of Support services will not contain any names,
or personal or protected information. Socio-demographic variables, age, gender, marital status, and comorbidities will be retrieved. Data will be maintained on the server and the co- investigator will work
on a VA computer in a locked office on the VA premises.
9.

Indicate the procedure for assuring that method(s) used during data collection protect the privacy of the
participants (for example, recruitment, obtaining of consent, or obtaining of data will be done in a
private location or manner). Note: this does not refer to the confidentiality of the data. No identifiable
data will be available in the reports.
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The data collected on the questionnaires will contain no names or any other individually identifiable
data. The reports available will contain no personally identifiable data that can be connected back to
the individual participants.
10. Does the protocol involve immediate or future testing of genetic material and/or pedigree studies?
Yes X No
If yes, briefly describe any additional means (other than those described in 8) that will be used to protect
the confidentiality or anonymity of the subjects. In addition, standard wording must be added to the
consent document that cautions prospective subjects about the hazards of identifiable genetic findings
toward future insurability and/or employability. See suggested wording in “Cover Letter/Consent
Form Guidelines” (http://www.wright.edu/rsp/IRB/Consent_Guide.doc). In addition, wording should
be added indicating compliance with the Genetic Information Nondiscrimination Act (GINA). See
http://www.wright.edu/rsp/IRB/GINA.pdf for further information.
Request for waiver of consent is made because the proposed study cannot be practicably conducted
without a waiver of authorization. Consent would be a document which would subsequently link
subjects to the study, increasing the risk to their privacy. The study is being conducted at several sites,
which would also require secure transport of materials.
11. Have adequate safeguards been taken to protect against identifying, directly or indirectly, any
individual subject in any report of the research project? X Yes
No If No, provide further
information.
12. Is identifiable medical information (Protected Health Information or PHI) being collected during the
study?
Yes X No Refer to
http://www.wright.edu/rsp/IRB/Policies/P_19%20Using%20Protected%20Health%20Information%20
In%20Research.docxfor a list of PHI.
If yes, does the consent document follow the HIPAA requirements (refer to
http://www.wright.edu/rsp/IRB/Policies/P_19%20Using%20Protected%20Health%20Information%20
In%20Research.docxand to “Cover Letter/Consent Form Guidelines”
(http://www.wright.edu/rsp/IRB/Consent_Guide.doc).
Yes
No
If the consent document does not follow the HIPAA requirements, is a waiver of the HIPAA privacy
rule being requested? (Note: this is most commonly requested with studies limited to chart review) X
Yes
No
If a waiver is being requested, all of the following questions must be completely answered:
a.

Explain why the research cannot reasonably be conducted without the waiver of
authorization.
Consent would require collection of data about participants which would subsequently
link them to the study, increasing the risk to their privacy. The study is being conducted
at several sites, which would also require secure transport of materials.

b.

Explain why the research cannot reasonably be conducted without access to and use of
identifiable health information.
There is no identifiable information being collected.
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c.

Briefly describe the PHI (Protected Health Information) for which use and/or disclosure
has been determined necessary.
There is no identifiable protected health information being collected.

d.

Describe the reasonable safeguards to protect identifiable information from unauthorized
use or re-disclosure.
There is no identifiable information being collected. Reports will be secured on the
computer in a locked office in the VA. The reports and data will be destroyed upon
completion of the study.

e.

Describe the reasonable safeguards to protect against identification, directly or indirectly,
any patient in any report of the research.
No names or any identifiable information will appear on any questionnaire or report since
all data will be utilized in an aggregate manner.

f.

Describe the plan to destroy the identifiers at the earliest opportunity, consistent with the
research. If there is a health or research justification for retaining identifiers, or if the law
requires you to keep such identifying information, please provide this information as
well.
The reports and data will be destroyed upon completion of the study.

g.

Provide written assurance that identifiable information will not be reused/disclosed to any
other person or entity, unless such use is required by law, for oversight of the research
study, or for other research permitted by law.
No data will be utilized for any purpose other than this study.

13. Will a Certificate of Confidentiality be requested from NIH?



Yes

X No

If yes, does the Consent Form advise the subjects of situations where the PI may voluntarily
comply with state laws?
Yes
No
If yes, has the standard confidentiality statement been modified to be consistent with
Confidentiality Certificate protections? See http://grants.nih.gov/grants/policy/coc/index.htm.
Yes
No

STUDY SITE RESOURCES:
14. Is this study a multi-center study for which the PI at WSU is the lead investigator or WSU is the
coordinating site of the study? X Yes
No
If yes, are there procedures in place for the PI or WSU to adequately manage the protection of human
subjects (such as Adverse Events (AEs), modifications and progress reports) at all the research sites? X
Yes

No. If no, please explain

15. You may either answer the following questions or attach a separate page (check here if a separate page
is attached)
a.

State where you will be conducting the research study (e.g. Wright State University (WSU),
Veterans Administration (VA), Good Samaritan Hospital (GSH), Miami Valley Hospital
(MVH), etc.)
Include the address for any site not affiliated with WSU
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Name of site(s): Veterans Administration Medical Center-Dayton, Louis Stokes
Veterans Administration Medical Center; Cincinnati Veterans Administration
Medical Center; Chalmers P. Wylie Ambulatory Care Center; Chillicothe
Veterans Administration Medical Center
If other than WSU, Dayton Clinical Oncology Program (DCOP) or hospital
facility, describe the facility where the study will be conducted

b.

How will the PI ensure that all research staff for the study are adequately informed of the
research-related duties and functions? The co-investigator has completed CITI training

c.

Are there adequate resources to complete the research study? X Yes

No

d.

Is there access to a population that will allow recruitment of the required number of
participants?
X Yes
No If no, explain how subjects will be recruited in item 17, below.
e.

If previously collected deidentified data is being used in the research (for example, publicly
available datasets), briefly describe the source (leave blank if non-applicable)
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RECRUITMENT:
16. Will this research study recruit any subjects from the following “Vulnerable” categories? Check all
that apply.
Cognitively Impaired
Fetuses
Pregnant Women
Prisoners
Healthy Volunteers (applies only to more than minimal risk protocols)
Others vulnerable to coercion (e.g. employee of research site or sponsor, students of
investigator). Describe:
Minors (<18 years of age)
For research involving minors, please indicate which of the categories listed below
accurately describes this protocol (refer to the appropriate section of 45CFR46, Subpart
D)
Not involving greater than minimal risk (46.404)
Involving greater than minimal risk but of direct benefit to individual subjects
(46.405)
Involving greater than minimal risk, no direct benefit to individual subjects, but
likely to yield
generalizable knowledge about the subject disorder or condition (46.406)
Involving research not otherwise approvable which presents an opportunity to
understand,
prevent, or alleviate a serious problem affecting the health or welfare of minors (46.407)
17. Describe the population from which the researcher will recruit (or data source from which data will be
obtained):
Individuals attending the workshop will decide whether to allow their data to be utilized in the study.
Note: if subjects are being recruited at a non-WSU site (e.g. local schools, prisons etc.) provide a copy
of the permission to use that site signed by an institutional official, or, equivalently, approval from
their IRB.
18. How will participants be recruited for this study? Attach copies of any materials given to prospective
subjects and/or scripts of any oral communication used to recruit subjects.
Individuals attending the workshop will decide whether to allow their data to be utilized in the study
19. What type of advertising will be used for this study? Check all that apply.
Note: If an advertisement is to be used, WSU policy requires prior written approval from the PI’s
department chair and dean. A copy of the advertisement with approval of the chair or dean must be
submitted with this application for IRB review.
No advertising will be used
Newspaper
Poster
Brochure
Web Site
Internet
E-mail
Radio or TV
Patient Recruitment Letter
(script)
X Other (describe) A handout will be provided by the class leader to recruit participants, a copy of
which is attached to the protocol.
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20. State the approximate expected number and age range of participants to be enrolled. List each group,
arm, cohort, etc. if applicable, including control groups, on separate lines. If only one group,
description would be “All.” Check “N/A” if the only data used in the study will come from a
previously existing, deidentified data source. N/A
(Note: This applies to exempt studies only)

Group

NUMBER OF SUBJECTS
All sites for
All other sites
which you are
the PI
30-80
30-80

Dayton
Columbus

AGE RANGE OF SUBJECTS
All sites for which
All other sites
you are the PI
18-100
18-100

Cleveland

30-80

18-100

Cincinnati

30-80

18-100

Chillicothe

30-80

18-100

a.

Are subjects who might otherwise benefit from the research excluded from participation?
Yes X No. If yes, provide scientific and ethical reasons for excluding these subjects
.

b.

Is the subject population representative of the population base from which subjects could
be selected with respect to gender representation (see NIH guidelines at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm).

X Yes
c.

No. If no, please explain.

.

Is the subject population representative of the population base from which subjects could
be selected with respect to minority representation (see NIH guidelines at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm).

X Yes

No. If no, please explain.

.

21. Will subjects be paid or otherwise compensated?

Yes

X No

N/A. If yes:

a.

What is the amount of the compensation?

b.

If not monetary, what will be used for compensation?

c.
d.

What is the reason for compensation?
If subjects are to be remunerated, indicate how this remuneration will be prorated over
the course of their participation.

22. Will the research involve the intentional use, of or introduction into, subjects of:
a.

Biohazards (e.g. rDNA, microorganisms, biological toxins) requiring approval by the
Institutional Biosafety Committee?
Yes X No
b. Radioisotopes, radiation, or x-rays requiring approval by the Radiation Safety Committee:
Yes X No
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c.

Hazardous chemicals (not covered elsewhere in this petition) requiring approval of
Environmental Health and Safety?
Yes X No
23. Does the protocol involve exposure to human blood or body fluids by study personnel?
No
If yes, have study personnel received appropriate training?
that will be taken to ensure that training occurs

Yes X

Yes

No (If no, describe the steps

No

N/A. If yes, describe and

).

24. Are there anticipated costs to study participants?
justify the costs:

X Yes

Some participants, depending on their VA eligibility, will pay a co-payment for each class session.
This is not related to the study.
INFORMED CONSENT:
25. Is the short form process for obtaining consent going to be used in the study (if the short form for
consent will be used, the complete process that will be followed for obtaining short form consent must
be described and attached. See WSU Standard Operating Procedures, Policy 12 – Obtaining Informed
Consent in Human Subjects Research atwww.wright.edu/rsp/subjects.html).
Yes X No
26. Is deception being used in the study (which prevents the full purpose of the study from being disclosed
in the consent document)?
Yes X No
If Yes, then a waiver of informed consent must be requested (by responding to question 29).
27. Will there be a consent document used in this study? (A consent document is usually a signed consent
form, but may also be a cover letter or an introduction to a survey).
Yes X No If No, a waiver
of informed consent must be requested (by responding to Question 29).
a.

If yes, will the consent document be signed?
Yes
No If No, then a waiver of
informed consent documentation must be requested (see question 28)

b.

If the consent document is going to be signed, who will be signing? (Indicate all that may
apply):
Participant (adult)
Participant (minor, signing an assent) with parent or guardian signing permission
Legally authorized representative for participant
Next of kin for participant (emergency research only)

28. For unsigned consent documents (e.g. when the consent information is found in a cover letter or a
survey introduction) please indicate the rationale for waiving the documentation of informed consent
by checking the appropriate box below. Also, please be sure that you have included a rationale for
using an unsigned consent document in your research protocol. The waiver of documentation can only
be approved if it meets one of the following two categories:
X The only record linking the subject and the research would be the consent document and
the principal risk would be potential harm resulting from a breach of confidentiality.
or
The research presents no more than minimal risk of harm to subjects and involves no
procedures for which written consent is normally required outside of the research context.
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29. If there will not be a consent document used in the study (e.g. as in studies limited to retrospective
studies such as chart reviews), or if the consent document will not include all the required elements of
informed consent (Refer to http://www.wright.edu/rsp/IRB/NewProtocolReviewChecklist.doc) (which
is the case if deception is being used in the study) then a waiver of consent must be requested by
answering the following questions. A waiver can be granted only if the answer to all of the following
questions is “Yes”.
a.

The research involves no more than minimal risk to the participants. X Yes

No

b.

The waiver or alteration will not adversely affect the rights and welfare of the participants. X Yes
No

c.

The research could not practicably be carried out without the waiver or alteration. X Yes
No

d.

The research is not subject to FDA regulation. X Yes

e.

If deception is used, the subjects will be debriefed after participation.

f.

That for any person for whom consent has not been obtained, whenever appropriate, additional
pertinent information will be provided after participation.
Yes
No X N/A

No
Yes

No X N/A

30. Informed consent involves more than obtaining the subject’s signature on a consent form. It is a
process between the investigator and the subject that involves sharing information and addressing
questions and concerns to allow the subject to fully understand what they are agreeing to. For
complicated protocols, or for subjects with limited comprehension, it is often appropriate to include an
assessment of comprehension as part of the consent process.
Please describe the process by which informed consent will be obtained and documented by answering
the following questions. This section does not need to be completed if a waiver of informed consent
has been requested and informed consent will not be sought from study participants.
a.

The consent interview (the opportunity for the subject to discuss the protocol with the
investigator or designee) will be conducted by:
Study staff
Investigator or co-investigator
Other (describe)
N/A (e.g. if the consent process does not involve contact between the investigator and
the subject)

b.

Will subjects have an opportunity to ask questions prior to signing the consent document?
Yes
No
N/A

c.

Will comprehension be assessed in some fashion (e.g. through use of a verbal or written
assessment test)? Note: This is not required for all protocols, but is appropriate for very
complicated protocols, or for protocols involving subjects with limited comprehension.
Yes
No
N/A

d.

Is there a waiting period between the consent discussion and the signing of the consent
document?
Yes
No
N/A

e.

Will participants be allowed to review the consent document at home prior to signing?
Yes
No

f.

Are there procedures in place to minimize the possibility of coercion or undue influence?
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Yes

No.

If No, please explain:

g.

Will the language to be used in the informed consent document and/or consent interview
No
be understood by the potential participants?
Yes

h.

If consent will be obtained from adults who are cognitively impaired on a temporary
basis at the beginning of the research, is there an opportunity (if appropriate) for these
No
participants to provide consent after recovery of cognitive function?
Yes
N/A

i.

Will a copy of the informed consent document be provided to the participant? If no,
please provide a justification.
Yes

No Justification if “No”

SIGNATURES AND CERTIFICATIONS
By signing and submitting this application, the Principal Investigator agrees that he/she:
1.

2.
3.
4.
5.
6.
7.

Accepts responsibility for the scientific conduct of the project, that the scientific portion of the protocol
is original and contains no false, fictitious, or fraudulent statements or date. Signature certifies that all
listed investigators have reviewed the proposal and that the research will be conducted in full
compliance with WSU policies and federal regulations.
Has provided the IRB with all the information on the research project necessary for its complete
review.
Will submit progress reports to the IRB for review in a timely manner in order to obtain appropriate
continuing review to maintain the approval status of the protocol.
Will submit all changes in the study to the IRB for review and approval before implementing those
changes.
Will submit anticipated problems (including adverse events) to the IRB for review in a timely manner.
Will not put this research project into effect until final IRB approval is received.
Has completed the required modules in the CITI training program, which can be found at
http://www.citiprogram.org/ (see also IRB Policy P.5.)

If this protocol involves more than minimal risk AND the research is or is proposed to be funded by an
external grant/contract, you must include two (2) copies of the external grant/contract proposal. [NOTE:
Grant/contract or proposals for external funding that is to be administered by Wright State University must
be processed through Research and Sponsored Programs.] One of the following two boxes must be
checked:
More than minimal risk AND externally funded; two copies of the proposal are included
X Not applicable
*DCOP protocols are assumed to be conducted under the umbrella NCI grant, a copy of which is
provided to the IRB separately. Thus copies of the DCOP/NCI grant proposal are not required to
be submitted with DCOP petitions.
Signature of Principal Investigator

Date

All other Investigators and/or Faculty Advisor listed on the cover of this petition (if
any) must sign to acknowledge their participation in this project:
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Signature of Faculty Advisor

Date

Signature of Co-Investigator

______________________________________
Date
Signature of Co-Investigator

Date

Signature of Co-Investigator

______________________________________
Date
Signature of Co-Investigator

Date

Signature of Co-Investigator

______________________________________
Date
Signature of Co-Investigator

Date

Signature of Co-Investigator

______________________________________
Date
Signature of Co-Investigator

Date

Signature of Co-Investigator

______________________________________
Date
Signature of Co-Investigator

Date
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Appendix J
Letter to Participants – Dayton Only
Welcome to the Healthy U Class.
Purpose of Study
My name is Dr. Beth Cameron and I am the Health Promotion Program Manager at the
Dayton VA Medical Center. I am inviting you to take part in a research study about the
Healthy U class. The purpose of this study is to see if there is a difference in how you feel
about managing your chronic disease before and after completing the workshop. The
Dayton VA Medical Center and the Wright State University Institutional Review Board
have given my team permission to conduct this study. The research team includes
Healthy U leaders and a graduate nursing student from Wright State University.
Description of Study
As many as 100 Veterans may agree to participate in this study. We are conducting the
study at all the VA centers in Ohio. If you agree to be part of it, we will ask you to do
these following things:




Complete a survey of six questions on the first day of your Healthy U class. This
will take you about five or ten minutes.
Take the same survey of six questions a second time, but only if you have
attended four of the six sessions of the class and the last class.
Give permission to the VA Division of Support Services, which is part of the VA
system, to get certain information from your medical record. We want to know
these things about the Veterans who take this class:
o Your age
o Your marital status
o Your gender
o Whether you have heart disease, high blood pressure, diabetes, depression
or arthritis
o How many times you have visited a VA medical center or CBOC

Confidentiality
We will make every effort to keep your personal information private. We will not ask
you to put your name any of the surveys. The Division of Support Services will get
information from your records electronically after receiving your name from the class
leader by VA-protected email.
We will not use your name or any personal information that can identify you in any
reports or published papers that may result from the study. The study reports will not
have names on them. We will not be able to trace information back to any individual
person. We will keep all information in locked files at all times. Only we will have access
to these files.
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Risks and Benefits
There are no risks to you from this study. There are no direct advantages to you if you
agree to be part of this study. We hope that the results from this study will make more
self-management programs like this one possible.
Your Rights
It is your decision if you would like to be part of this study. Your decision will not
change your Healthy U classes or your care in the VA system in any way. You may
decide that you do not want to be part of the study at any time. You do not have to give a
reason for not participating. Making that choice will not affect your care or classes in any
way. If you have questions about this study, you may contact me at 268-6511, Ext. 2527.
You may also contact:
 Joan Sevy Majers, the WSU graduate nursing student, at 937-768-5559;
 The Wright State University Institutional Review Board, at 937-775-4462.
Thank you for taking the time to read this information. If you are willing to be part of this
study, please complete the attached survey and return it to your class leader.
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Appendix K
Final Approval - Dayton
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Appendix L
Approval - Dayton Research and Development Committee

DEPARTMENT OF
VETERANS AFFAIRS

Date: April 25, 2013
From: Coordinator, Research and Development Service
Subj : Approval of Proposal
To:

Beth Cameron (1 lP)
Joan Sevy Majers

1.

The Research & Development Committee reviewed:

A.
Program"

Study name: "An Evaluation of the Chronic Disease Self-Management

B.

Proposal number: 552-13-006, SC 5041

C.

On (date): April 23, 2013

Your proposal was approved.
2.
You may begin your research study. Please note this approval is effective
only through January 25, 2014. This approval will automatically expire on this
date unless you submit a "continuing review" request at
http://www.wright.edu/rsp/IRB/CR sc.doc and send this document to the
Research Office.
3.

If you have any questions, please contact the Research Office at x1156.

Jack M. Bernstein, M.D.
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Appendix M
IRB Close-Out Report
Wright State University Research and Sponsored Programs
Human Subjects Protection, Institutional Review Board

FINAL STUDY CLOSE-OUT REPORT FORM
INSTRUCTIONS
 Use this form to close out any WSU IRB-approved study.
 Submit this completed form within 30 days of completion or termination of all
research activity for a study, even if the current approval period has expired.
 Do not close out a study if any of the following six conditions apply. Such studies
must remain active and continue to receive ongoing IRB review and approval.
1. Enrollment at the WSU-approved site is ongoing
2. Research-related interventions and/or follow-up at the WSU-approved site is
ongoing
3. Participant follow-up at the WSU-approved site is ongoing.
4. Biological specimens containing personally identifiable information are being
maintained in a repository that has been approved as part of this study or upon
which analysis or research is ongoing. If, however, specimens were transferred to
a separate repository that has ongoing IRB approval, the study may be closed.
5. Data analysis or manuscript preparation is ongoing.
6. If there is an external study sponsor and the sponsor has not provided permission
to close the study with the IRB
 Return one hard copy of this form and any supporting materials to:
WSU IRB 201 University Hall Wright State University Dayton, OH 45435
 Contact IRB office if you have any questions.
 Call the IRB staff at 937-775-4462 or email robyn.wilks@wright.edu
 Refer to the full procedure for Project Closures, Suspensions, and Terminations on the
WSU RSP web page
(http://www.wright.edu/rsp/IRB/Policies/P_10%20Suspensions%20and%20Terminatio
ns.doc)

A. PROTOCOL INFORMATION:
Currently Approved Principal Investigator

Beth Cameron, DNP,RN
Project Title

An Evaluation of the Chronic Disease Self-Management Program
WSU IRB #

Expiration Date

SC-5041

1/25/14

B. STUDY STATUS AT CLOSE OUT:
1. Provide the reason for closing the study at WSU:
[ ] Study was completed. (Please complete sections B through G.)
[X ] Study was started but closed prior to completion (Please complete sections B
through G.)
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[ ] Study was not started. (Please indicate reason below and skip sections C through F).
[ ] Study is being transferred to another institution. (Please indicate institution below in
B.4.)
2. Please explain why the study was not started or was closed prior to completion.
The Veterans Affairs Health System implemented a new process for access to the
outcome data required for the study. These new requirements resulted in procedures that
made these data unavailable to the researchers.
3. Did the study involve the collection, storage,
or use of any human biological specimens? If
yes, please explain what will happen with the
specimens at the close of this study.

[ ] Yes [X ] No

4. Which institution is this study being transferred to? What parts of the study are being
transferred? Be sure to work with your Department to make sure everything you need
to do to transfer the study has been or will be completed.

C. SUMMARY OF STUDY RESULTS:
1. Please summarize the results of this research project.
42 participants completed the initial survey prior to the workshop; 39 completed the survey after the
workshop. The surveys were totally anonymous. Statistical significance could not be measured, since the
results were not paired, but the average mean perceived self- efficacy measured prior to the workshops was
6.09. After completion of the workshops, participants’ mean perceived self-efficacy measured and measured
8. 167.The pre-survey mean results were two points lower than the average mean post-survey, indicating a
definite difference.

2. Have there been any presentations or publications resulting from this
study since last continuing review. If yes, please describe and cite
references.

[ ] Yes [X
] No

D. SUBJECT RECRUITMENT AND ENROLLMENT since last initial or continuing
review:
1. Was there any participant contact since the date of the last review?
If no, skip sections E through F.
[X ] Yes [ ]
If yes, answer the questions below in this section only for subjects
No
since the last initial or continuing review.
2. Number of subjects enrolled since the last continuing review (if there
has been no continuing review, please record the number of subjects
42
enrolled during the study).
3. Approximately how many potential subjects have refused participation?
unknown
4. How many subjects have voluntarily withdrawn from participation?
unknown
5. How many subjects have been withdrawn from participation by the PI?
none
6. If applicable, provide a brief summary below of any difficulty obtaining/retaining
subjects, or obtaining informed consent since the last continuing review.
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Participants were invited to complete a pre-survey at the first workshop class. To be included in the final sample, they
would have had to have attended four of the six sessions and to have completed the second survey. Of the 42 original
participants who completed the initial survey, 39 completed the second. It is not known if they failed to attend the four
of six sessions, did not attend the last session to complete the last survey, or chose not to complete a final survey.

E. SIGNIFICANT FINDINGS AND REPORTABLE EVENTS
1. Have there been any significant new findings (recent literature or
other relevant information) that may affect the risks or benefits
associated with the research that should be disclosed to subjects who
have participated in the study?
If yes, please describe below and describe how you will notify
research participants. Submit copies of any materials that you use to
notify participants.

[ ] Yes [X] No

2. FOR BIOMEDICAL OR HIGH RISK BEHAVIORAL STUDIES ONLY: Reporting and
Summary of 10-Day Reportable Adverse Events and Other Safety Information:
a. Are you submitting any new or missed Adverse Event Reports now? [ ] Yes [ ] No
b. Are you submitting any new or missed DSMB or other multi-center
[ ] Yes [ ] No
oversight reports now that were not submitted previously?
c. Were there any other unexpected safety developments that the IRB
[ ] Yes [ ] No
should know about? If yes, please explain below.
3. Reporting and Summary of Protocol Violations, Deviations and/or Incidents:
a. Are you submitting any new or missed 10-day Violation, Deviation or
[ ] Yes [X ] No
Incident Reports now?
b. Were there any other unexpected developments in study conduct
that the IRB should know about (e.g., problems with study activities [ ] Yes [X ] No
or participant complaints)?
If yes, please explain below.

F. STUDY ACTIVITY AFTER IRB APPROVAL EXPIRATION: Please answer the
following questions only if the WSU IRB approval has expired.
If the WSU IRB approval for this study has expired, did any researchrelated activity(ies) occur during the lapse in approval? If yes, answer
[ ] Yes
the questions below.
If the WSU IRB approval for this study has expired, did any researchrelated activity(ies) occur during the lapse in approval? If yes, answer
[ ] Yes
the questions below.
1. Were any participants enrolled during the lapse of approval period?
[ ] Yes
2. Did any other research-related activity(ies) continue during the lapse
[ ] Yes
of approval period? .
3. Why did the approval lapse occur?

[ ] No

[ ] No
[ ] No
[ ] No

4. What will be done do to prevent this from happening in the future for other studies?
5. If yes to either questions #1 or 2, please describe all research-related activities that
continued, including number of participants involved and any adverse events,
violations, deviation or incidents that occurred during the period of protocol lapse:
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G. PRINCIPAL INVESTIGATOR’S CERTIFICATION:
I certify that all study activity involving participant contact, or use or access to individually
identifiable information has ceased and the information provided in this report is complete
and correct.

Principal Investigator's Signature

Date
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Appendix N
Study Information for Healthy U Trainers
Purpose of the study: This study will evaluate the impact of the Stanford University
Chronic Disease Self-Management Program (CDSMP) on volunteer participants. All
VISN 10 VA facilities implemented the program in FY12 and plan to expand it in FY 13.
Because there are limited data about outcomes for the CDSMP among Veterans, this
evaluation is being done to assess the effect of the program in VISN 10.The study is
focused on outcomes that include 1) a self-report of self-efficacy at the beginning and end
of the CDSMP workshop, and 2) a comparison of utilization of healthcare resources in
the six-month period before the workshop and the six-month period after the workshop.
During the first class, please identify the Veteran participants and provide them with a
copy of the study handout (sample attached).
1. If the Veteran chooses to participate in the study, provide them with a copy of the
study survey and ask them to complete the six questions. It is important to remind
them not to place their name or any other personal information on the survey
(sample attached).
2. Collect the surveys and mark each with the letter “A”.
3. Place the surveys in the addressed envelope that has been provided and keep it
with your class materials until the last class.
4. At the last class, ask the Veteran participants who completed the first survey and
attended at least four of the six classes if they would complete another survey.
5. If the Veteran completes this second survey, please remind them again not to
place their name or any other personal information on the survey.
6. Collect the surveys and mark each of these with the letter “B”.
7. Place these surveys in the same envelope with the previous surveys marked “A”.
Seal the envelope and either return it to your master trainer or place it in the
outgoing VA mail.
8. From the class list, delete the names of the individual participants who:
a. Elected not to participate in the study by not completing an initial survey
b. Are not Veterans
c. Completed an initial survey, but did not attend at least four of six sessions
d. Elected not to complete a second survey
1. Send that class list with names and the last four digits of their social security
numbers, or amended class list, via encrypted e-mail, to beth.cameron@va.gov.
Participants may ask you how and why we are accessing their medical records and how
we are protecting their privacy and confidentiality. The names are sent being sent by
encrypted e-mail through the VA firewall. The researchers are looking for characteristics
of the class participants that can be pulled from their electronic medical records, such as
age, marital status and their chronic diseases. However, the report that will be generated
by the Division of Support Services (a VA department) will have no names or any
identifiable information on it. Since the surveys also do not have any names on them,
there will be no way the researchers can link these results back to any of the individual
study participants either.
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Appendix O
Survey Tool

Self-Efficacy for Managing Chronic Disease
6-Item Scale
We would like to know how confident you are in doing certain activities. For each of the
following questions, please choose the number that corresponds to your confidence that
you can do the tasks regularly at the present time.

Not at all
Confident
1.

1

2

3

9

2

3

4

5

6

7

8

9

10

2

3

4

5

6

7

8

9

10

2

3

4

5

6

7

8

9

10

2

3

4

5

6

7

8

9

10

How confident are you that you can do the different tasks and activities
needed to manage your health condition so as to reduce your need to see
a doctor?
1

6.

8

How confident are you that you can keep any other symptoms or health
problems you have from interfering with the things you want to do?
1

5.

7

How confident are you that you can keep the emotional distress caused
by your disease from interfering with the things you want to do?
1

4.

6

How confident are you that you can keep the physical discomfort or pain
of your disease from interfering with the things you want to do?
1

3.

5

How confident are you that you keep the fatigue caused by your disease
from interfering with the things you want to do?
1

2.

4

Totally
10 Confident

2

3

4

5

6

7

8

9

10

How confident are you that you can do things other than just taking
medication to reduce how much your illness affects your everyday life?
1

2

3

4

5
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Appendix P
Request for Data - Division of Support Services
IMPORTANCE
Chronic disease impact
The prevalence of chronic diseases is rising. In 2005, nearly 133 million
Americans had at least one chronic disease. By 2020, that number is anticipated to
increase by 16% to 150 million or more. Many Veterans have more than one chronic
illness. Symptoms of chronic illnesses - including pain, fatigue, muscle tension, shortness
of breath, and depression - can be debilitating and interfere with normal life activities.
Although medical treatments and medications are crucial in the management of chronic
disease, disease outcomes are heavily impacted by the decisions that patients make every
day about physical activity, food intake, stress management, and adhering to a medical
plan of care.
Individuals with chronic conditions consume a lot of healthcare resources, and they have
been found to utilize more services, at greater expense, as the numbers of their chronic
conditions multiply. Much of the growth in health care spending is related to the care of
individuals with chronic conditions. The burden of chronic disease in the veterans
Affairs health system is estimated to be similar if not greater than in the general
population. Utilization of healthcare services and costs of care for Veterans increases
with the number of identified chronic conditions.
Self-management program expectations
The CDSMP is one of several self-management programs have been designed to help
patients make healthy decisions, manage symptoms using self-care strategies, work with
their healthcare team, and use the healthcare system more efficiently. Approaches like
these, if effective, could help contain or reduce costs, and also improve the quality of life
for those with chronic diseases.
PROGRAM DESCRIPTION
CDSMP description
The Chronic Disease Self-Management Program was developed in 1996 by Stanford
University with a grant from Agency for Healthcare Research and Quality. The program
consists of six structured workshops presented weekly to participants with any chronic
disease. The purpose of the program is to build participants’ confidence in managing their
health and to teach them the skills of chronic disease self-management.
•
VISN implementation description
•
Collaborations
Association with VA mission & objectives, other initiatives at VA
The Department of Veterans Affairs continues to pursue excellence in the delivery of
care and services. In its proposed strategic plan for 2014-2020, goals have been identified
to achieve success. Goal one, states” Empower Veterans to improve their well-being”
and includes achieving outcomes from “preventative care and healthy lifestyle changes”.
PROGRAM GOAL(S)
•
Attendance, # leaders trained, # classes
•
Affecting ability to self-manage care, changing the responsibility
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TARGET AUDIENCE:
All participants from the program inception who have
attended at least four of the six sessions of the workshops
Data elements:
a. Demographics: age, race, gender, marital status
b. Hospital days, ED visits, provider visits six months prior to the first workshop day
(identified by the Healthy U note)
c. Hospital days, ED visits, provider visits six months, after the last workshop
day(identified by the Healthy U note)
PROGRAM IMPACT
•
Description of population/attendees, trainers trained
•
Attendance
•
# workshops, #sites, # workshops per site, # leaders trained
•
# participants & their demographics
•
Resource utilization data points – another decision point for DSS questions
What unanticipated issues arose?
ADMINISTRATION
•
Cost, including time & staff investment in project
•
Source of funding
•
Management – personnel needs
•
Marketing effectiveness – publicity, promotion, advertising
•
Conflicts with other programs?
DECISIONS
•
Are we reaching the target population?
•
Suitability for VA sites
•
Is the program cost effective?
•
Should we continue the program?
•
Should we alter the program?
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participant
number
(sequential)

gender

age

marital
status

# of sessions
ethnicity attended

date of 1st
session
attended

date of last
session
attended

For the six month prior to first session
# of
# of ED
hospital visits
days
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# of
provider
visits

# of
hospital
days*
cost of
average
hospital
day

# of ED
visits *
cost of
average
ED visit

For the six months after the last session

# of
# of
# of ED
provider
hospital visits
visits * cost days
of average
provider
visit

# of
# of
provider hospital
visits
days*
cost of
average
hospital
day

# of ED # of provider visits *
visits * cost of average
cost of provider visit
average
ED visit

Appendix Q
Tests for Normality, Paired Sample
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Appendix R
Paired Sample Statistics

Paired Differences
95% Confidence Interval of

Mean
Pair

prior_ADMITS -

1

post_admit

Pair

prior_cost_bdoc -

2

post_cost_bdoc

Std.

Std. Error

Deviation

Mean

the Difference
Lower

Sig. (2-

Upper

t

df

tailed)

-.667

.816

.333

-1.524

.190

-2.000

5

.102

$-

$1.38565E4

$5,656.9012

$-1.55536

$1.35295

-.179

5

.865

$-2.11749

$3,515.9132

-1.838

5

.125

1.01203E

7

3
Pair

prior_in_cost -

3

post_in_cost

$-

$1.17639E4

$4,802.5822

8.82952E

3

6

3
Pair

prior_LOS - post_LOS

-2.500

36.215

14.785

-40.505

35.505

-.169

5

.872

-.529

2.741

.665

-1.939

.880

-.796

16

.438

$-

$1,786.7360

$433.34714

$-1.37433

$462.98047

-1.052

16

.309

455.6744

5

4
Pair

prior_ER_visits -

5

post_ER_visits

Pair

prior_ER_cost -

6

post_ER_cost

4
Pair

prior_OUT_visits -

7

post_out_visits

Pair

prior_out_cost -

8

post_out_cost

1.978

23.267

1.981

-1.938

5.895

.999
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.320

$898.529

$1.57000E4

$1,336.4746

$-1.74426

$3,541.3159

.672

137

.503

26

6
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Appendix S
Paired T-Test: Nonparametric Tests
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Appendix T
Total Sample: Tests for Normality
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Appendix U
Total Sample: Group Statistics
Group Statistics
pre_post

N

Mean

Std. Deviation

Std. Error Mean

pre

139

.19

.537

.046

post

139

.19

.680

.058

20

8.40

16.223

3.628

post

15

14.93

22.212

5.735

pre

20

$33,787.87

$22,061.494

$4,933.100

post

15

$43,682.50

$34,328.852

$8,863.672

pre

20

$11,439.49

$8,772.736

$1,961.643

post

15

$7,456.53

$7,821.891

$2,019.604

pre

38

2.24

1.807

.293

post

31

2.68

2.482

.446

pre

38

$1,060.27

$912.993

$148.107

post

31

$1,419.31

$1,554.215

$279.145

pre

38

$479.48

$121.764

$19.753

post

31

$512.19

$109.145

$19.603

42.88

34.665

2.940

admits

los

inpatient_cost

cost_bdoc

ER_visits

ER_cost

cost_per_ER_visit

out_visits

out_costs

pre

pre

139

post

138

41.17

40.360

3.436

pre

139

$17,619.40

$16,906.576

$1,433.997

post

138

$16,845.19

$19,451.432

$1,655.816

pre

139

$390.01

$202.029

$17.136

post

138

$392.45

$323.599

$27.547

per_out_visit

147

